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Abstract
The objective of this study was to utilise click chemistry to develop novel types of
18

F labelled carbohydrates for use in positron emission tomography imaging through

the coupling of [18F]-fluoroalkynes with various 1-azido sugars and 2-azido sugars. In
total, eight novel compounds were synthesized in this study.
The products of the click reaction between various types of alkynes and 1-azido
sugars, the 1,2,3-triazole sugars, were afforded in good yields. Two hydroxy triazole
sugars prepared in this manner were fluorinated and used as cold standards for HPLC
analysis and identification of the analogous radiolabelled material. It was subsequently
demonstrated that 1-azido glucosamine could be succesfully labelled with fluorine-18
in just 8 mins via a click reaction using 4-[18F]-fluoro-1-butyne.
The above work was then extended to the preparation of 2-azido sugar triazoles,
which widens the scope of click reactions on 2-azido sugars as only a few examples
have been reported in the literature. Further extension of the work to the conjugation of
1-azido glucosamine and 1-azido glucuronide methyl ester with an acetylenic phenol,
provided new examples of sugar triazole compounds which might be labelled with
fluorine-18 using the same methods as those used to radiolabel the well known imaging
agent fluoroethyltyrosine.
In summary, the click reaction is a very useful method for radiolabelling
carbohydrates, which can be achieved in short reaction times and in good yield. The
methodology that was developed here can be used to modify various bioactive peptides
with radiolabelled carbohydrates to generate new types of cancer imaging agents.
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CHAPTER 1
INTRODUCTION

Chapter 1: Introduction
1.1 Cancer and angiogenesis
Cancer is a major disease in many developed countries and accounts for one in
every fours deaths in the United States.1 Cancer is a complex disease composed of a
varied population of rapidly growing and dividing cells that have lost the ability to
divide and grow in a controlled process. However, this rapid rate of tumour cell growth
and proliferation cannot grow beyond a certain size (generally 1-2 mm3), primarily due
to the lack of oxygen, essential building blocks and energy. To facilitate their growth,
the tumours secrete various biochemicals called growth factors such as Vascular
Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) to
induce blood vessel growth and thus sustain and nourish the rapidly growing tumour
mass. This induction of blood vessel growth by the tumours is called angiogenesis.
Angiogenesis is also required for the spread or metastasis of a tumour. Single
cancer cells can break away from an established solid tumour, enter the blood vessel,
and be carried to a distant site, where they can implant and begin the growth of a
secondary tumour. The subsequent growth of such metastases also requires a supply of
nutrients, oxygen and a waste disposal pathway. Although angiogenesis is an essential
step in the transition from a small harmless cluster of cells, to a large tumour, it is also
necessary for normal organ growth, wound healing and repair, and embryonic
development inside the womb and after birth.2
The process of angiogenesis occurs when stimulators and chemicals (which are
naturally synthesized by the human body) that prevent angiogenesis are not balanced. A
fluctuating balance between these pro- and anti-angiogenic stimuli results in an
‘angiogenic switch’.2 This term refers to the progression of the tumour and metastasis,
where the tumour changes from a small and localized tumour to a growing, spreading
cancer. The tumour sends the signals to the cells lining nearby blood vessels
1
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(endothelial cells). Once the switch is turned on, the endothelial cells will grow and
multiply, enzymes will be directed to clear a pathway to the tumour and blood vessels
will form new stems to reach the tumour. Above all, there are a series of events
involved in the angiogenesis process (Fig.1.1). Ever since it was proposed in the 1970s
by Dr. Judah Folkman, inhibition of angiogenesis is considered to be one of the best
and most effective strategies to treat and save a cancer patient.3

Fig. 1.1: An orderly series of events in the angiogenesis process.4

Endothelial cells have long been considered genetically more stable than cancer
cells. This genomic stability confers an advantage to targeting endothelial cells using
anti-angiogenic therapy, compared to chemotherapy directed at cancer cells, which
rapidly mutate and acquire 'drug resistance' to treatment. For this reason, endothelial
cells are thought to be an ideal target for therapies directed against them. Angiogenesisbased tumour therapy relies on natural and synthetic angiogenesis inhibitors like
angiostatin, endostatin and tumstatin.

2
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1.2 Integrins
Integrins are cell surface receptors that interact with the extracellular matrix and
mediate various intracellular signals. They are very important in cell adhesion and cellcell communication in the human body. Integrins are non-covalent heterodimers
consisting of α and β subunits.5 Integrins have been widely studied, and to date 18 α
and 8 β glycoprotein integrin subunits have been discovered. They are expressed on the
cell surface in 24 different heterodimeric combinations and named as integrins αxβy.6
The size of the α subunit is between 120-180 kDa with around 1000 amino acids,
while the β subunit is between 90-110 kDa with around 700 amino acids.7,

8

Each

subunit has a large extracellular domain, a single membrane and a short non-catalytic
cytoplasmic tail, except for integrin β4 (Fig.1.2). The integrin α subunits contain 4
domains and there are 8 domains in the β subunits.8, 9 Some α subunits, especially αv
have been shown to associate with more than one β subunit and both the extracellular
domains of the α and β chain have been identified as ligand binding sites.10, 11

Fig.1.2: General structure of integrin.12

3
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Integrins function in signal transduction events and play a major role in cell
adhesion, proliferation, apoptosis, polarity, shape, gene expression and differentiation.13
Particular integrins are known to play a critical role in lymphangiogenesis (α9β1),
thrombus formation (αIIbβ3) and the integrity of skin (α6β4). β3-Integrins also have a
role in enhancing angiogenesis, wound healing, inflammation and atherosclerosis.13 In
2002, an interaction between αv-integrin and the matrix proteins vitronectin and
tenascin in brain tumours was found. 14
Integrins also play a key role in cancer metastasis,15 with recent evidence showing
that αvβ3 integrin is an important regulator of angiogenesis.16 Most of the integrin
recognition sequences, including those of α5β1, αvβ1, αvβ3 and αvβ5, share features with
the ligand Arg-Gly-Asp (RGD).13 Therefore, angiogenesis antagonists based on RGD
peptides have been extensively investigated both as new types of anticancer agents and
as cancer imaging agents.

1.3 Radiopharmaceuticals for imaging cancer
In the field of nuclear medicine, tracers used for diagnosis and therapy are known
as radiopharmaceuticals,17,

18

and they consist of two parts; the compound and the

radioisotopic label.19 A bioactive molecule is labelled with a radionuclide forming the
radiopharmaceutical ligand, which then binds to a specific receptor or protein that is
connected to the target, for example a tumour cell. Radiopharmaceuticals can be
administered to the patients by injection, orally, or placed directly into the organs or
tissues such as the bladder, eye and even a solid tumour. The initial biodistribution of
the radiopharmaceuticals generally reflects the blood flow to areas of the major organs.
Over time the radioactivity will accumulate in the targeted organs and wash out from

4
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areas of the body which do not represent specific targeting. The radioactivity will then
be detected and an image produced by the respective imaging equipment.
Today there is much interest in developing radiopharmaceutical ligands that are
highly selective and bind to specific sites on the tumour, thus providing critical
metabolic and biochemical information about the tumour. An important aspect of
radiopharmaceutical development is the pharmacokinetic optimisation of the compound
that will ultimately provide the required contrast of the image. There are many
radiopharmaceutical ligands that have been developed and are already in clinical use,
and others still in preclinical studies, which bind to specific receptors20, 21 and target
diseases such as proliferation, angiogenesis, apoptosis and metastasis (Fig. 1.3).

Fig. 1.3: Radiopharmaceutical ligands already in the clinic (bold) or in clinical studies (italic).20

In general, radiopharmaceuticals must fulfil common criteria such as high
specificity and affinity to the target molecule, rapid blood clearance, low plasma
binding, good in vivo stability and low radiation dose to critical organs. In addition, the

5
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labelling process should include a minimum of radiosynthetic steps, be produced in
high radiochemical yield and purity, and high specific activity.20, 21

1.4 Radionuclides
Radionuclides are unstable isotopes that undergo radioactive decay to achieve
stability.22,

23

The radioactivity comes from a spontaneous decay process that emits

electromagnetic radiation such as gamma( )-rays or charged alpha ( ) and beta ( )
particles. The type of emission that is emitted is very important in determining whether
the radionuclide is suitable for imaging or treatment of patients.23
The penetrating power of gamma radiation is more than that of charged particles.22
It can pass through the body and is ideal for use in external imaging.24 In contrast, for
therapeutic uses, the objective is to destroy the tumour mass, hence a low penetration is
needed to minimize harm to surrounding healthy tissue.22 As alpha and beta radiation
consists of particles that can’t penetrate far into the body, they are restricted to the
target tissue and are suitable for therapeutic purposes.25
There are several factors that should be considered in selecting radionuclides for
medical use such as the type of radiation emitted, the half life, energy of the radiation,
dose minimisation to the patient and detection characteristics.22,

23, 26

Ideally, the

synthesis and imaging of the radiopharmaceuticals must be within a time frame
compatible with the radioisotope’s half life.27 If the half life is too short, the compound
will not reach a maximum target to background ratio as most of the radioisotope would
have already decayed. In contrast, a too long half life makes the normal tissue exposed
to an unnecessary radiation dose.26 Some of the common radioisotopes used in nuclear
medicine are listed in Table 1.1.

6
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Table 1.1: Radionuclides of interest in nuclear medicine (adapted from Ref.22).
Radionuclide

Mode of decay

Principal Photons (KeV)a

Half-life

Used clinically, mainly for diagnosis
99m

Tc

IT

140

6 hrs

I

EC

159

13 hrs

TI

EC

167

73 hrs

+

511

20 mins

123
201
11

C

18
68

F

+

, EC

511

110 mins

Ga

+

, EC

511

68 mins

Used clinically, mainly for therapy
32
89

P

-

None

14.3 days

Sr

-

None

52 days

β- 0.5 MeV

6.7 days

γ, 208 keV
364

8.1 days

177

Lu

131

a

I

γ, β-

-

Values in parentheses are % emission frequency. IT = isomeric transition; EC = electron capture.

Radiopharmaceuticals incorporating the positron emitting radioisotopes such as
fluorine-18, carbon-11, nitrogen-13 and oxygen-15 have been used to study specific
biochemical functions in the human body. Furthermore, as carbon, nitrogen and oxygen
constitute the basic building blocks of most physiologically important biochemical
compounds, carbon-11, nitrogen-13, and oxygen-15 can be conveniently incorporated
directly into biomolecules.22,

27

However, except for fluorine-18, the use of these

radionuclides is confined to clinical research centres with in-house cyclotrons due to
their very short half lives.

7
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1.5 Positron emission tomography
Medical imaging techniques provide invaluable information on the status of disease
in the body. There are several different techniques used such as ultrasound, computed
tomography (CT), magnetic resonance imaging (MRI), positron emission tomography
(PET) and single photon emission computed tomography (SPECT).
Ultrasound, CT and MRI are anatomical imaging methods that provide good
anatomical information on the status of disease, however, they do not have the ability to
provide biochemical information such as tumour growth, response to therapy, and early
response to biochemical treatments.28 PET and SPECT on the other hand are functional
imaging modalities that have the ability to measure the regional biochemistry especially
in early detection of the disease based on molecular and biochemical processes.28, 29
PET imaging has become an important technique to study physiological,
biochemical and pharmacological functions in humans. It is a non-invasive imaging
technique that can measure the concentration of the tracer in tissues accurately due to
its high sensitivity and high spatial resolution.30, 31 SPECT has a problem in collimation
and attenuation resulting in a reduced ability to quantitate the distribution of
radiotracers compared to PET.19 In addition, several important positron emitters
(carbon, nitrogen and oxygen) are also the physiologically important elements.32
Therefore, PET is a very useful method for both treating and monitoring cancer.
In PET, once the radiopharmaceutical is given to the patient, the positron, or
positive electron, travels no more than a few millimetres in the tissue and then collides
with a negative electron.19 The resultant annihilation process creates two gamma rays of
511 keV each, which travel in opposite directions33 (Fig.1.4). These rays that are 180
degrees apart will be detected by a scintillator in the camera, which after computer
processing can produce an image of the physiology and biochemistry in vivo.

8
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Fig. 1.4: Mechanism of annihilation.34

The most common positron emitters are 15O (t1/2= 2.07 min),
11

C (t1/2= 20.4 min) and

18

13

N (t1/2= 9.96 min),

F (t1/2= 109.7 min) which are produced on particle

accelerators called cyclotrons. By far, the most common radiopharmaceutical used in
PET imaging is 2-[18F]-fluoro-2-deoxy-D-glucose, or [18F]FDG.

1.5.1 [18F]-Fluoro-2-deoxy-D-glucose, [18F]FDG
[18F]FDG is one of the most widely used PET radiopharmaceuticals and is
commercially available in most advanced countries. [18F]FDG is a glucose analogue
whereby the hydroxyl group on carbon-2 is replaced by a fluorine atom. [18F]FDG is
prepared by nucleophilic substitution of a triflate precursor (Scheme 1.1). Based on
glucose, [18F]FDG is transported across cell membranes and is then phosphorylated by
hexokinase.22 The absence of the hydroxyl group of [18F]FDG in the carbon 2-position
prevents further metabolism, hence it is retained in the cell for a longer time allowing
imaging of the tumour to take place.22, 35

9
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Scheme 1.1: Synthesis of [18F]FDG by nucleophilic substitution.35

[18F]FDG is not only very useful in evaluating many malignancies but also for the
staging and detection of recurrence for many tumour types.36 However, its specificity in
cellular dynamics in regards to energy requirements has limited its use in molecular
imaging.37 Normal fast growing cells, such as brain and pancreatic cells can also take
up [18F]FDG making it a non-cancer-specific tracer. Furthermore, slow growing
tumours have a low [18F]FDG uptake, making them difficult to image. Nanni et al. have
addressed the issue that there is a need for new PET radiopharmaceuticals other than
[18F]FDG as there are still many biological aspects of cancer that cannot be measured
by [18F]FDG alone.38

1.6 Radiolabelled peptides
Amino acids are the building blocks of peptides and are linked together through
peptide bonds. Proteins or peptides are found in all living things. More than 80
polypeptide drugs have made it into the market and are approved for usage such as
teriparatide which is used for osteoporosis treatment and etanercept for the treatment of
rheumatoid arthritis.39 Rationally, since many of the cell surface receptors for peptides
are overexpressed in cancer, the interest in developing peptide radiopharmaceuticals
has risen.40 Peptides are chosen because of their size, with up to about 50 amino acids
and 10,000 Da in molecular mass, which is considerably smaller than monoclonal
antibodies resulting in more rapid blood clearance thus providing superior imaging
characteristics.31, 40, 41

10
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To date, several peptides were developed such as octreotide, bombesin, annexin V
and endothelin analogues that have been used for diagnosis and therapy in oncology,
neurology, cardiology and infection/inflammation. Various techniques have been
developed in labelling these peptides using radionuclides such as
18

99m

Tc,

123

I,

111

In and

F, with 111In–labelled octreotide the first radiopeptide approved for diagnostic tumour

imaging.31 A comparison of the advantages and limitations of the various radionuclides
used for peptide labelling is listed in Table 1.2.
Table 1.2 :Characteristics of different radionuclides used for peptide labelling 42
Advantages
Technetium-99m
Readily available, low cost
Easy to handle
Reasonable half life-6 h
140 keV γ-emission
Excellent imaging characteristics
Absence of α and β radiation
Favourable dosimetry
Iodine-123
159 KeV γ-emission
13 h half life
Good imaging characteristics
Cyclotron-produced radionuclide
Indium-111
171 and 245 KeV γ-emission
Half life of 2.8 days
Useful for acquiring delayed images

Fluorine-18
Can be produced in high quantity
Low positron energy of 0.635 MeV
High resolution and sensitivity
Low radiation dose to patients
The half-life of 110 min permits both
radiopharmaceutical preparation and
imaging studies

Limitations

Relatively more difficult
incorporate into small drugs

to

High cost
Limited availability

High cost
Limited availability
Relatively high radiation burden to
patients
Suboptimal nuclear characteristics

Relatively short half-life

As described before, integrins especially those of the αvβ3 subtype play important
roles in many intracellular signalling pathways. Therefore, integrins are an effective
target of radiopeptides as some of the integrins such as αvβ3, αvβ5, αvβ1 and αIIbβ3 are

11
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recognised by the Arg-Gly-Asp (RGD) sequence.40,

43

The first generation of RGD

radiotracers were the cyclo(-Arg-Gly-Asp-D-Tyr-Val-) and cyclo(-Arg-Gly-Asp-DPhe-Tyr-) that when labelled with iodine-125, showed high affinity and selectivity to
αvβ3 in vitro and receptor specific tumour uptake in vivo.44, 45 But, these tracers have
high concentrations in the liver due to their lipophilic character. To overcome this
problem, the peptide was modified and conjugated with a sugar amino acid based on
glucose. As a result, the radio-iodinated gluco-RGD showed high tumour uptake with
an improved pharmacokinetic profile.46
Based on these results, radiofluorination of the cycloRGD peptide was developed
by attaching a sugar amino acid based on galactose to the cyclic RGD peptide followed
by conjugation with [18F]fluoro propionic acid resulting in the generation of
[18F]galacto-RGD (Fig. 1.5). The [18F]galacto-RGD displayed reduced lipophilicity and
enhanced renal excretion compared to the non-glycosylated analogue,45 and ultimately
advanced into clinical imaging of αvβ3-integrins in melanoma patients.20

Fig.1. 5: The structure of [18F]galacto-RGD.45

PET imaging often uses

18

F due to its favourable physical and nuclear

characteristics.47 To date, several radiofluorinated conjugates have been developed for

12
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the radiofluorination of peptides and proteins including N-succinimidyl 4[18F]fluorobenzoate ([18F]SFB), 4-nitrophenyl-2-[18F]-fluoropropionate ([18F]NPFP)
and 4-[18F]fluorobenzoic acid ([18F]FBA) (Fig.1.6). Peptide labelling is achieved by
conjugation to three functional groups: the amino group, the carboxylic acid group and
the sulfhydryl group.47,

48

[18F]NPFP was used in the labelling of [18F]galacto-RGD

resulting in both high radiochemical yield and purity.45 Above all, [18F]SFB was
reported to be the most useful for radiofluorination and peptide labelling.49

O

O

NO 2

O
O

18

N
O

18

F
[18 F]SFB

F

O
CH3
[ 18F]NPFP

Fig. 1.6: Structures of N-succinimidyl 4-[18F]fluorobenzoate (SFB) and 4-nitrophenyl-2-[18F]fluoropropionate (NPFP).

1.6.1 Click chemistry
The most disadvantageous aspect of labelling with 18F is the use of time consuming
multi-step reactions, and there is still great need for method improvement in this area.
Table 1.3 shows some of the different approaches for labelling biomolecules with 18F.
Click chemistry is a recent discovery which uses fewer chemical reactions and
milder conditions to generate labelled substrates compared to other current methods.50
It has become a powerful and selective reaction employed in various fields of
chemistry.51 The term “click chemistry” was introduced by Sharpless et al., who
followed nature’s lead to join small units together with heteroatomic links (C-X-C).
The click reaction is high yielding and easy to perform using readily available reagents
and starting materials. It is also tolerant to water, and the subsequent work-up and
product isolation are straight-forward.52, 53 An attractive feature of the click reaction is

13
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that it can be performed without protecting groups due to the chemoselectivity in the
reaction.54
Table 1. 3: Different approaches for labelling biomolecules with 18F. (Adapted from ref.47, 55 )
18
Method
F labelling agent
Preparation
Radiochemical
time (min)
yield (%)
18
Acylation
4-Nitrophenyl-2-[ F]fluoropropionate [NPFP]
90
60
Imidation

N-Succinimidyl-4 [18F]fluorobenzoate [SFB]
3- [18F]Fluoro-5-nitrobenzimidate

Alkylation

35-100
45

25-60
20-23

4- [18F]Fluorophenacyl bromide

75

28-40

Photochemical
conjugation

4-Azidophenacyl- [18F]fluoride

15

71

Click reaction

[18F]fluoroalkynes

10-15

36-81

Click chemistry utilises the Huisgen 1,3-dipolar cycloaddition reaction of terminal
alkynes and organo azides to form 1,2,3-triazoles (Fig.1.7). The most widely used click
reaction is a Cu(I)-mediated reaction that produces only the 1,4-regioisomer. In contrast
the thermal reaction is non-regiospecific.56

Fig. 1.7: The ’click reaction’ of an azide and terminal alkyne to give a 1,2,3-triazole.56

A variety of Cu(I) sources have been used in the Huisgen cycloaddition reaction
including CuI salts such as copper iodide57 and copper bromide,58 however, this type of
reaction needs a large of excess of copper and ligand to work efficiently.59 The use of
metallic copper has also been employed, however, the reaction with copper turnings
took a long time to form the desired triazole in good yield.51 Despite this, the most

14
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common click reactions use an in situ reduction of a Cu(II) salt system to produce
Cu(I),such as Cu(II) sulfate with sodium ascorbate as reducing agent. The advantages
of this system is it is cheap, does not require an inert atmosphere, can be perfomed in
the presence of water and eliminates the need for a base.51, 60
Generally, cycloadditions proceed through a concerted mechanism.60 However,
density funtional theory calculations showed that copper catalysed reaction proceeds in
a stepwise mechanism (A→B→C→D) rather than a concerted process (A→D)
(Fig.1.8).51, 61 The Huisgen 1,3-dipolar cycloaddition begins with formation of a Cu(I)
acetylide via -complexation, then deprotonation to form the -acetylide Cu(I) complex
A, followed by generation of the copper-azide-acetylide complex B, cyclisation and
dissociation to yield the desired triazole product and the copper catalyst ligand
(Fig.1.8).51, 61

Fig.1.8: Catalytic cycle of the Huisgen cycloaddition.61

The use of click chemistry has now expanded into the radiochemistry field, where
the Cu(I)-mediated coupling of an azide and alkyne has been used to form labelled
triazole containing compounds. The first peptide labelling using click chemistry was
introduced by Marik and Sutcliff and demonstrated that peptides could be efficiently
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labelled with [18F]alkynes in high yield, under mild conditions, and with rapid
preparation times of 30 min.62 Other labelled compounds using click chemistry which
have been developed are 4-[18F]fluoro-1-butyne that was used in the first radiolabelling
of a sugar azide,63 2-[18F]fluoroethylazide in terminal alkyne labelling,64 [11C]methyl
azide in the generation of

11

C-labelled 1,2,3-triazoles65 and metal chelated

99m

Tc

labelled biomolecules66 (Fig. 1.9).

Fig. 1.9: Radiolabelled compounds produced using “click chemistry’.

1.6.2 Carbohydrates
Carbohydrates are widely represented in biological systems and the most abundant
group of natural products.67 Recently, carbohydrate-containing derivatives have
attracted much interest in drug development. This is because the incorporation of a
sugar moiety is often found to improve the pharmacokinetic profile of a drug. It has
been reported that conjugation of a sugar into the peptide backbone and / or side chains,
can improve its pharmacological properties including bioavailability, stability of the
drug toward enzymatic degradation and solubility under physiological conditions.45, 68
Carbohydrate derivatives bearing an amino acid and a carboxylic acid moiety, also
known as sugar amino acids (SAAs), are of particular interest.69 SAAs are easy to
synthesise from commercially available monosaccharides such as glucose, glucosamine
and galactose. The amino functionality of the SAA can be introduced as an azide,
cyanide or nitromethane, while the carboxylic function can be introduced directly as
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CO2 or as a hydrolysable cyanide.70 SAAs can be employed as structural analogues in
mimics of Leu-enkephalin integrin antagonists (RGD), somatostatin, cyclodextrins and
as pharmacophore mapping libraries.71 SAAs have been incorporated into cyclic
peptides not only to improve the pharmacokinetic profile of the drug but also to
introduce radioisotope labelling in order to allow imaging.70
In addition to SAAs, sugar diamino acids (SDAs) have recently emerged as an
interesting new building block in peptidomimetic chemistry (Fig. 1.10). SDAs have the
potential to be even more useful building blocks than SAAs, as they have both an amino
and carboxylic acid moiety available for peptide coupling and an additional amino
moiety available for labelling or other types of modification. For example, protected
SDAs have been used in the development of RNA ligands based on the incorporation
of the binding motifs from naturally occurring aminoglycosides into nonnatural
synthetic analogues by combinatorial methods.71 Although SDAs hold great potential,
their synthesis is quite challenging and there is much room for method development in
this area. To date, only two types of SDAs have been reported.69,

72

Fig.1.10 shows

examples of some of the known SAAs and SDAs.

Fig. 1.10: Examples of sugar amino and sugar diamino acids.

17

Chapter 1: Introduction
1.7 Project aims
Carbohydrates such as FDG have been widely used in cancer imaging. Recently, it
has also been found that the incorporation of certain carbohydrate moieties into peptide
based tumour targeting and imaging agents such as cyclo-RGD improves their
biodistribution and pharmacokinetic profile. We were interested in generating novel
analogues of cyclo-RGD through the attachment of radiolabelled carbohydrates to the
available lysine residue (see Fig. 1.5). There is also much scope for the inclusion of
radiolabelled carbohydrate moieties into a whole range of existing pharmaceutical
agents. Furthermore, new methods for labelling carbohydrates and new types of
labelled carbohydrates are much needed in this area. Thus the aims of the project are:
To utilise click chemistry to develop novel types of

18

F labelled

carbohydrates for use in PET imaging through the coupling of [18F]fluoroalkynes with various 1-azido sugars and 2-azido sugars.
To extend the methodology developed above to the labelling of sugar amino
and sugar diamino acids, which have a free carboxylic acid or amino moiety
for coupling to tumour targeting agents such as the peptide cyclo-RGD.
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Chapter 2: Results and Discussion (Part I)
This chapter details the utilisation of click chemistry in the development of
novel types of

18

F labelled carbohydrates for use in PET imaging on their own and/or

attached to tumour targeting agents. The development of methodology for the coupling
of alkynols with 1-azido glucosamine derivatives via click chemistry, followed by
fluorination of hydroxyl triazole sugars will be presented in the first part. The chapter
closes with the successful generation of an [18F]-radiolabelled sugar derivative.

2.1 Labelling of 1-azidoglucosamine (2) with aliphatic alkynes

Scheme 2.1: General scheme for glycosylating and subsequent radiolabelling of tumour targeting agents.

Carbohydrates are often used to modify the properties of bioactive peptides
including their biodistribution and pharmacokinetic profile. The project described here
involves the use of click chemistry to prepare radiolabelled carbohydrates that could
readily be coupled to bioactive peptides such as cyclo RGD to generate novel imaging
agents with improved properties. The carbohydrate starting materials for this project
require both an azido group for click chemistry and either a carboxylic acid or an amino
functionality to attach to the peptide of interest using standard peptide coupling
conditions. An example of this type of glycosylation and subsequent radiolabelling of a
tumour targeting agent is shown in Scheme 2.1.
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Fig. 2.1: A sugar amino azido acid (1) and the model amino azido sugar (2).

Sugar diamino acids (SDAs) bearing two amino groups (or an amino and azido
group) and a carboxylic acid residue would be the ideal candidates for this type of
chemistry ((1), fig.2.1). However, there are few reported SDAs in the literature and their
synthesis is still largely in the developmental stage. SDAs such as (1) are difficult to
synthesize so the commercially available 1-azidoglucosamine (2), was used as a
simplified model of a SDA for this project. This sugar still has a free amino group for
coupling to bioactive peptides and/or tumour targeting agents along with an azido group
for click reaction (Fig. 2.1).
The general strategy behind the first part of the work is shown in scheme 2.2 and
involves a click reaction between the commercially available 1-azidoglucosamine (2)
with the alkynols (3) and (4), to give the hydroxy triazoles (5) and (6), which are
converted to their fluoro derivatives (7) and (8). These latter compounds are used as
cold standards for the HPLC purification and identification of the analogous
radiolabelled material (Scheme 2.2a).
There were two routes then used to obtain the radiolabelled target (12). The first
route involved subjecting the sugar (2) to a click reaction followed by radiofluorination
(Scheme 2.2b). The second route involved radiofluorination prior to the click reaction
(Scheme 2.2c). That is, the alkynols (3) and (4) could be converted to the [18F]fluoroalkyne derivatives (13) and (14) and coupled to (2) to give the radiolabelled
targets (11) and (12) as shown in Scheme 2.2c.
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Radiolabelling of 1-azido sugars via click chemistry using the fluoroalkyne (14)
has been reported in the literature.63 However, the use of the homologous fluoroalkyne
(13) is novel and would expand the existing library of fluorination precursors for
radiolabelling. The radiolabelling of (2), as shown below is described in detail in the
following section.
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Scheme 2.2: Various strategies to label the 1-azidoglucosamine (2).

There are several examples in the literature of 1-azido sugars undergoing click
reactions to give a range of products including (15)73, (16)74, (17)75, (18)76 and (19)77 in
good yields as shown in Fig 2.2. The click reaction has been found to be a useful
method for the glycosylation of peptides, for example to produce the alanine-type
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derivative (17)75 through the click reaction of an azido amino sugar and amino acid.
However, most of the reported work in this area is not involved with the radiolabelling
of sugars and therefore the proposed work using click chemistry for the radiolabelling
of carbohydrates is novel. This work will also be a useful expansion to the existing
research on sugar-click chemistry and potentially generate a new class of drugs based
on glycosylated peptides.

Fig 2.2: Selected examples of the products from reported click reactions on 1-azido sugars.

2.1.1 Click reaction of 1-azidoglucosamine (2) with alkynols (3) and (4)

Scheme 2.3: The click reaction of 1-azidoglucosamine (2) with alkynols (3) and (4).
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Reported methods utilising click conditions, e.g., CuSO4 and sodium ascorbate in a
tert-butanol / water mixture (1:1), were used to synthesise both the known hydroxy
triazole (5) and the novel derivative (6) (Scheme 2.3).63 Analysis of the 1H NMR
spectra of the known derivative (5) is in accordance with the literature data for this
compound.76 The 1H NMR spectra of the novel derivative (6) is similar to that of the
homologue (5), as shown in Table 2.1. The full 1H and

13

C NMR assignments of the

novel compound (6) were based on 2D NMR data derived from gHSQC and gHMBC
experiments, while 2D gCOSY experiments were done on the known compound (5).
The structure of (6) was confirmed by assignment of the additional two protons of the
methylene carbon to a multiplet peak at

2.99 with an integration of two protons.

Further key 1H and 13C spectral assignments of compound (6) are shown in Fig. 2.3.

Fig. 2.3: Key 1H and 13C NMR spectral assignments for tetrazole (6) shown in blue and green respectively.

In addition, a molecular ion peak at, m/z 465 in the ESI mass spectrum was
assigned to the MH+ ion of the hydroxyl sugar (6), with the (M + Na)+ formula of
C18H26N4O9Na confirmed by HRMS with a peak at, m/z 465.1596 compared to the
calculated value of 465.1597. The optimisation of the reaction conditions afforded 74%
of the known compound (5) and 94% of the novel compound (6), both as single
products not requiring chromatographic purification. This is evidence, as proposed by
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Kolb and co-workers, that click reactions have simple work-up procedures and are
highly selective for a single product.52
Table 2.1: 1H, 13C and selected 2D NMR (CDCl3, 400 MHz) data for the novel triazole sugar (6) and the
known triazole sugar (5).
(6)
Position

C

H

[m, J (Hz)]

(5)
gHMBCa

b
C

H

[m, J (Hz)]

gCOSY

1

86.2

6.08 (d, 9.8)

2

90.0

6.03 (d, 9.9)

2

2

53.8

4.63 (q, 9.8)

1, 3

57.4

4.62 (q, 10.1)

3, 1,
NH

3

72.2

5.53 ( t, 9.4)

2, 4, C(O)CH3

77.9

5.47 (t, 10.0)

2, 4

4

68.2

5.28 ( t, 9.7)

3, C(O)CH3

67.3

5.28 (t, 9.8)

3, 5

5

74.9

4.11 (m)

C(O)CH3

73.4

4.01 (m)

4,
6a,6b

6a

61.8

4.19 (dd, 12.6,
2.2)

C(O)CH3

78.7

4.14 (dd, 12.6,
2.0)

6b

6b

61.8

4.33 (dd, 12.6,
4.9)

C(O)CH3

78.7

4.29 (dd, 12.6,
4.9)

6a

1’

-

-

-

-

-

-

2’

-

-

-

-

-

-

3’

-

-

-

-

-

-

4’

145.9

-

1”

148.0

-

5’

121.5

7.88 (s)

1”, 2”, 5’

121.3

7.83

1”

29.1

2.98 (m)

2”, 4’, 5’

56.1

4.80 (s)

2”

61.4

3.89 (m)

1”

-

-

-

-

OH

-

OC(O)CH3

OC(O)CH3

NHC(O)CH3

-

169.4

d

170.7

d

170.8

d

2.07 (s)

20.7c
20.7c

20.6

171.2

NHC(O)CH3

22.7

c

-

c

NHC(O)CH3

a

e

d

4
3, 6a, 6b
3, 6a, 6b

2.67 (bs)

174.8

d

-

174.9

d

-

175.0

d

-

C(O)CH3,
C(O)CH3

25.7

c

2.04 (s)

2.08 (s)

C(O)CH3,
C(O)CH3

25.9c

2.07 (s)

2.09 (s)

C(O)CH3,
C(O)CH3

26.0c

2.10 (s)

7.13 (d, 9.1)

C(O)CH3

-

-

-

175.5

1.74 (s)

C(O)CH3

27.8

6.23 (d, 9.0)
d

2

1.76 (s)

Protons correlated to carbon resonances in the C column. bLiterature values for
Assignments may be switched. dAssignments may be switched.

C,

ref.76
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2.1.2 Fluorination of the hydroxy triazole sugars (5) and (6)

Scheme 2.4: Fluorination of the hydroxyl compounds (5) and (6) using diaminosulfur trifluoride(DAST).

The fluorination of the hydroxy triazole sugars (5) and (6) was carried out using
diethylaminosulfur trifluoride (DAST), which is a common fluorinating agent for the
conversion of aliphatic alcohols into alkyl fluorides.78, 79 The synthesis of the methyland ethylfluoride derivatives (7) and (8) was based on procedures in the literature
(Scheme 2.4).63,

78

The preparation of these compounds was performed in order to

obtain a cold (i.e. non-radioabelled) standard to be used in authenticating the

18

F-

radiolabelled derivatives and in developing HPLC conditions for radiolabelling,
purification and quality control (see Section 2.1.7).
In the analysis of the 1H NMR spectra of the methyl fluoride derivative (7), a peak
at

5.44-5.56 ppm, which appeared as a broad doublet with an integration of two

protons and a coupling constant of 48 Hz, clearly showed the splitting of two protons
by the fluorine atom in the fluoromethyl moiety. The splitting is due to the coupling of
hydrogens with a fluorine atom which has a spin of ½, and typically gives short range
coupling constants between protons and fluorine of about 47 Hz and long range
coupling constants of around 25 Hz.80 For the ethyl fluoride derivative (8), the structure
of the product was confirmed by the presence of two mutually coupled, doublet of
triplet peaks in the 1H NMR spectrum at 3.10-3.19 and 4.63-4.78 with an integration
of two protons each, which could be assigned to the four protons in the two methylene
carbons.
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In addition, molecular ion peaks at, m/z 453.1 and 467.1 in the ESI mass spectra of
the above compounds was assigned to the MH+ ion of the fluoro compounds (7) and (8)
respectively. Furthermore, the (M + Na)+ formulae of C17H23N4O8NaF and
C18H25N4O8NaF were confirmed by HRMS with peaks observed at, m/z 453.1393 and
467.1577 compared to the calculated values of 453.1398 and 467.1554 respectively.
The low yields obtained in the synthesis of these two compounds, (7) and (8), may
be due to some decomposition occurring prior to, and after, purification. This is based
on observations from thin layer chromatography (TLC) that was performed 30-45 min
after the reaction, and then again before and after the purification step. Furthermore,
preparative TLC was required to isolate the fluoromethyl derivative (7) after initial
fractionation by gravity column chromatography was not successful. To minimise any
further decomposition, the fluorinated derivatives (7) and (8) were kept at -18 oC in the
freezer. Although the yields for these compounds were low, they were adequate for the
required purpose, which was to obtain a cold standard for HPLC. The next step after
this reaction would be the deprotection/removal of the acetyl groups, whereupon the
product could also be used as a cold standard for HPLC.

2.1.3 Synthesis of propargyl tosylate (20) and butynyl tosylate (21)
The radiolabelled target systems for this study are the
and (12), which will be prepared using

18

18

[F]-fluoro triazoles (11)

[F]-fluoride. DAST can be used for the

fluorination of the triazole alcohols (5) and (6), however, it is not available as a
radiolabelled reagent, and therefore a good leaving group (such as the tosyl group)
needs to be introduced so that the radiofluorination can be performed by a nucleophilic
substitution reaction. There are two options to prepare the tosylated compounds (9) and
(10), the first is via a click reaction of the 1-azido glucosamine (2) with the alkynols (3)
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and (4) then tosylation of the hydroxyl triazole (5) and (6) (Scheme 2.2b). The second
option involves the tosylated alkynes (20) and (21) which can be clicked with (2) to
form the tosylated derivatives (9) and (10).

Scheme 2.5: A strategy to radiolabel the target system (12) by employing a click reaction with the
tosylated alkynes (20) and (21).

Tosylation of propargyl alcohol (3) and butynyl alcohol (4), in the presence of
triethylamine as a base to remove the hydrochloric acid formed from the reaction with
tosyl chloride (22), was performed in order to prepare the tosylated alkynes (20) and
(21) (Scheme 2.6).63 These alkynes could then be used either in a click reaction with 1azido glucosamine (2), to prepare the tosylated triazoles (9) and (10) as precursors for
the radiofluorination step (Scheme 2.5), or in the preparation of the [18F]-fluoroalkynes
(13) and (14) (section 2.17) for the direct click attachment of the radiolabel to the
glucosamine (2) (Scheme 2.2c).
The tosylated products (20) and (21) were confirmed by analysis of their MS and
1

H NMR spectra. All signals were identical with those for the same compounds

reported in the literature.63, 81 The tosylated compounds (20) and (21) were obtained in
51% and 91% yield respectively, with an improved yield for (21) compared to the yield
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in the literature (72%).63 In contrast, the yield of (20) was lower than the reported yield
(96%).81

Scheme 2.6: Tosylation of the propargyl- and butynyl alcohols (3) and (4).

2.1.4 Attempted click reaction of 1-azido glucosamine (2) with various alkynes
Several different conditions were used to optimize the click reaction on the 1-azido
glucosamine (2) with different alkynes as shown in Table 2.2.

Table 2.2: Attempted click reaction on 1-azido glucosamine with different alkynes.
Entry

R

Reagents

Temp.
(oC)

Time

Yield
(%)

1
2

OH
OH

Ascorbic acid, H2O/Tert-butanol
Ascorbic acid, Sodium hydrogen carbonate,
H2O/Tert-butanol
Sodium ascorbate, H2O/Tert-butanol

50
RT

O/N
2h

10
67

3

OH

RT

2h

74

4

CH2OH

Ascorbic acid, Sodium hydrogen carbonate,
H2O/Tert-butanol
Sodium ascorbate, H2O/Tert-butanol

RT

2h

80

5

CH2OH

RT

2h

94

6

OTs

50

O/N

0

OTs

Ascorbic acid, Sodium hydrogen carbonate,
H2O/Tert-butanol
Sodium ascorbate, H2O/Tert-butanol

7

RT

2h

0

8

CH2OTs

Sodium ascorbate, H2O/Tert-butanol

RT

2h

0

The click reaction on 1-azido glucosamine (2) was successful with the propargyl(3) and butynyl alcohol derivatives (4) as shown in Entries 1-5. The use of sodium
ascorbate with H2O/ tert-butanol gave the best results and the highest yield of the
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desired compounds (Entries 3 and 5), while the combination of ascorbic acid and
hydrogen carbonate to form the sodium ascorbate under 50 oC and in an overnight
reaction, gave the lowest yields (e.g. Entry 1).
The attempted click reaction of 1-azidoglucosamine (2) with the tosylated alkynes
(20) and (21) (Entries 6-8) was carried out in order to prepare the tosylated triazoles (9)
and (10) which can be labelled directly with 18F (Scheme 2.2b and 2.5). Unfortunately,
the click reaction with the tosylated alkynes was unsuccessful (Entries 6-8). Based on
TLC analysis of the reaction mixtures, they appeared to go to completion with the
formation of a new product, however 1H NMR analysis of the crude reaction product
showed that the tosylated alkynes (20 and 21) had not “clicked” with the 1-azido
glucosamine (2), as there were no signals for a triazole proton (normally at 7.78- 8.03
ppm) present. The nature of the product obtained is unclear at this stage and this
reaction was not pursued further.

2.1.5 Attempted tosylation of the hydroxy triazole sugar (5)
As the click reaction of the 1-azido sugar (2) with the tosylated alkynes (20) and
(21) did not afford the tosylated triazoles (9) and (10), the preparation of these
compounds was attempted by tosylation of the corresponding hydroxyl triazoles (5) and
(6) (Scheme 2.7). This reaction was performed in order to compare the synthesis time
and yield of the radiolabelled targets (11) and (12) using two different routes (see
Schemes 2.2b and 2.2c).
An investigation into whether the click reaction followed by radiofluorination
(Scheme 2.2b), or radiofluorination prior to the click reaction (Scheme 2.2c), would
give higher yields and shorter synthesis times (as reported in the literature63) was
planned. The product of the reaction below (Scheme 2.7) could potentially be
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fluorinated directly with

18

F, however, the tosylation of the hydroxy triazole sugar (5)

was unsuccessful. This reaction was attempted two times.

Scheme 2.7: Attempted tosylation of the hydroxy triazole sugar (5).

The reaction was set up in 100 mg scale of (5) for the first attempt and 50 mg the
second time. In the first attempt the reaction was stirred at 0 oC for 3 h. The 1H NMR of
the crude product after the first work up showed only the triethylamine signal and
aromatic ring of the tosylate group but none of carbohydrate signal even though the
extraction afforded a large amount of crude material. Then re-extraction of the aqueous
layer gave an additional 20 mg of crude product which consisted of some of the desired
compound (9) as detected by LRMS (ESI+).
In the second attempt the reaction was stirred at 0 oC for 3 h then left overnight at 4
o

C. The tosylated compound (9) should be less polar than the starting material (5),

however there was no such compound evident on the TLC. Instead, TLC analysis
showed the formation of several polar by-products and therefore the work-up was not
performed. The LRMS (ESI+) on the reaction mixture also did not show the presence of
peaks of matching those of the desired compound (9). Neither this reaction, nor the
attempt to tosylate the hydroxyl sugar (6) was investigated any further. In addition, the
literature showed that the route involving radiofluorination prior to the click reaction
(Scheme 2.2c) should give higher yields and shorter synthesis times for the
radiolabelled targets (11) and (12), and therefore we decided to change our strategy.63

30

Chapter 2: Results and Discussion (Part I)
2.1.6 Deprotection of the acetyl groups of the fluorinated compounds (7) and (8)

*
+&, ! %
! %

! %
$ %

Scheme 2.8: Deprotection of the fluorinated compounds (7) and (8) using sodium methoxide.

This reaction was carried out in order to investigate whether the click reaction
could be performed without the need for protecting the sugar hydroxyls as stated in the
literature.54, 63, 82 Once again, the products of this type of reaction, (23) and (24), could
be used as cold standards for developing the HPLC conditions for the radiolabelled
analogues. Unfortunately, the preparation of (23) and (24) using this approach was not
successful in obtaining the pure product.
Due to the low yield obtained for the preparation of the fluorinated starting
materials (7) and (8) (see section 2.1.2), the attempted deprotection of the acetyl groups
described above was performed on just 100 mg and without purification of the starting
materials (Scheme 2.8). This resulted in the production of numerous side products
based on TLC analysis. The 1H NMR spectra of the crude product also did not readily
show the presence of the desired product, although some of it was detected by LRMS
(ESI+). The attempted extraction of (23) and (24) from the reaction mixture gave a low
crude yield (~30 mg) and due to time constraints, the purification and repetition of the
reaction was not performed.
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2.1.7 Preparation of radiolabelled target (12)
The radiolabelling work described here was performed at ANSTO under the
direction of the radiopharmaceutical chemists (Dr Tien Pham and Dr Thomas Bourdier)
to show that labelling of carbohydrates with 18F can be readily achieved through click
chemistry. The method used follows the route described in section 2.1.5, i.e.
radiofluorination prior to the click reaction, and utilizes the fluorinated substrate (8) as
the cold standard for HPLC identification of the target (12) via peak matching.
The labelling of the 1-azido glucosamine (2) began with radiofluorination of the
tosylated precursor (21) to give 4-[18F]-fluoro-1-butyne (14) via nucleophilic
substitution (Scheme 2.9). To a dried K[18F]fluoride/Kryptofix222 complex the tosylated
alkyne (21) in acetonitrile was added and the reaction facilitated by heating, after which
micro-distillation was used to obtain the desired compound (14)62, 63 (Scheme 2.9). The
fluorobutyne (14) has a boiling point of 45 oC and was chosen as the preferred alkyne
to label the 1-azido glucosamine (2) as it is already used in the literature. Furthermore,
the lower boiling point of propargyl fluoride (15 oC) would make it more difficult to
handle.62, 63

Scheme 2.9: Labelling of 1-azido glucosamine (2) with 18F via a click reaction with the fluorobutyne (14).

With the radiolabelled alkyne in hand, the next step was the click reaction with the
1-azido glucosamine (2) (Scheme 2.9). Diisopropylethylamine (DIPEA, m.p. -50 oC)
was used for the click reaction during the radiofluorination instead of tert-butanol (m.p.
23-26 oC), as the latter would freeze during the distillation at -45 oC. DIPEA also gave
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the best results of the click reaction during the distillation to produce 4-[18F]fluoro-1butyne (14).50, 62, 63 The reagents were combined and the reaction stirred for 8 min after
which, the reaction mixture containing the desired radiolabelled product (12) was
filtered to remove any precipitate. The reaction mixture was then directly injected onto
a Bondclone 300 x 7.8 mm column, with a flow rate of 4 mL/min. A fraction was
collected between 7.0-13.4 min (Fig. 2.4), which showed 741 µCi of radioactivity.

mV

2.00

1.00

0.00

mV

40.00

20.00

0.00
0.00

10.00

20.00

30.00

Minutes
Fig. 2.4: HPLC traces of the reaction mixture from the preparation of (12) using a Bondclone 300 x 7.8
mm column (solvent: 20% ACN, 80% H2O, 0.1% TFA at 4 mL/min, λ= 226 nm). UV detector shown in
black and radioactivity detector shown in red.

An aliquot from this fraction, which contained 500 µCi, was co-injected with the
cold fluorine standard (8), with co-elution of the peaks between 12.7-13.6 min
confirming the presence of the radiolabelled target (12) (Fig. 2.5). The 4-[18F]fluoro-1butyne (14) was successfully synthesized in acetonitrile at 100

o

C in 50%
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radiochemical yield (unoptimised), while the click reaction to form the radiolabelled
compound (12) was successful at 90 oC for 8 min with a radiochemical yield of 22%
(unoptimised) and radiochemical purity of 80%.
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Fig. 2.5: Co-injection of the fluoro standard (8) (black) and the radiolabelled product (12) (red) on a
Bondclone 300 x 7.8mm HPLC column (solvent: 20% ACN, 80% H2O, 0.1% TFA at 4 mL/min, λ= 226
nm).

The 4-[18F]-fluoro-1-butyne (14) and the corresponding click reaction with the
azido sugar to give (12) was successfully synthesized in 50% and 22% radiochemical
yield respectively, however the reaction (temperature, time, solvent and concentrations
of reagents) and the microdistillation parameters were not yet optimised. The volatility
and efficiency of the 4-[18F]-fluoro-1-butyne (14) from a Wheaton microreactor using
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peak tubing during the reaction conditions (heating at 100 oC in acetonitrile) poses
further challenges with respect to yield losses and efficiency in transfers.
The radiochemical yield (RCY) obtained here which is 22%, via the click
chemistry are lower than the use of acylation method (RCY 25-60%) (Table 1.3). But it
is comparable using the imidation method (RCY 20-23%) (Table 1.3). In terms of time,
the use of the click reaction is superior which only took 8 min while the acylation and
imidation method took 35-100 min and 45 min respectively to complete.47
In summary, this chapter has detailed the preparation of the radiolabelled sugar (12)
derived from the commercially available 1-azido glucosamine (2). Deacetylation at C-2
of (12) would give a free amine which could be coupled to an available carboxylic acid
on bioactive peptides to potentially generate new imaging agents. The next chapter will
present the extension of the work on the click reaction to the preparation and
radiolabelling of 1-azido glucuronic acid derivatives, 2-azido sugar derivatives and the
use of other alkyne reagents such as 3-ethynylphenol.
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The radiolabelling methodology described in Chapter 2 was extended to the
labelling of 1-azido glucuronic acid derivatives, which can be coupled via the
carboxylic acid to the free amino moiety of appropriate tumour targeting agents such as
the peptide cyclo-RGD. The work was then further extended to the labelling of 2-azido
sugars and to the use of other alkyne reagents such as 3-ethynylphenol.

3.1 Labelling of 1-azidoglucuronic acid methyl ester (25) with aliphatic alkynes

Scheme 3.1: General scheme for glycosylating and subsequent radiolabelling of tumour targeting agents
with a free amino moiety.

In the first part of the study, an azido sugar bearing an amino group (protected as
NHAc) was employed, where the amino group could be made available for coupling to
a carboxylic acid-containing bioactive peptide and/or tumour targeting agent (Scheme
2.1). In the second part of the study, the aim was to extend the labelling methodology
described earlier to the labelling of 1-azido glucuronic acid methyl ester (25) as shown
in Scheme 3.2. Removal of the ester group by saponification would give a free
carboxylic acid at C-6, which could be readily coupled to a free amino group on a
tumour targeting peptide (Scheme 3.1). A similar strategy to that employed in Chapter
2 could be used to label the glucuronic acid derivative (Scheme 3.2).
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Scheme 3.2: Strategy for labelling1-azidoglucuronic acid methyl ester with fluoroalkynes.

3.1.1 Click reaction of 1-azidoglucuronic acid methyl ester (25) with alkynols (3)
and (4)

Scheme 3.3: Click reaction of glucuronic acid derivative (25) with propargyl (3) and butynyl (4) alcohol.

The click reaction of 1-azidoglucuronic acid methyl ester (25) with alkynols (3)
and (4) was performed according to Scheme 3.3. Analysis of the 1H NMR spectra of the
product obtained from the reaction with propargyl alcohol, showed a singlet peak at
4.79 with an integration of two protons, which was assigned to the two protons in the
methylene carbon, while another singlet peak at

3.74 was assigned to the three

protons of the methyl ester and a one proton singlet at

7.86 was assigned to the

triazole proton of (26), confirming that the click reaction was successful. The product
from the reaction with butynyl alcohol, that is compound (27), was confirmed by
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assignment of the additional two protons of the methylene carbon to a broad singlet
(likely to be an unresolved triplet) at

2.96 with an integration of two. In addition, the

(M + Na)+ formulae of C16H22N3O10 and C17H24N3O10 were confirmed by HRMS with
peaks at 416.1305 and 430.1451, compared to the calculated values of 416.1305 and
430.1462 respectively. 2D NMR experiments including gCOSY, gHSQC and gHMBC
were used in assigning the 1H and

13

C NMR spectra of compound (26), which then

assisted in the assignment of peaks in 1H and 13C NMR spectra of (27).
The products (26) and (27) were obtained as white solids in 23% and 83% yield
respectively. The low yield of (26) is because lots of starting material remained in the
reaction after 48 h based on TLC analysis. This reaction did not proceed further even
with the addition of aliquot of CuSO4/ Na ascorbate , and the product required
purification by gravity column chromatography to separate it from the starting
materials. In contrast, compound (27) was obtained in high yield after extraction from
the reaction mixture. Due to time constraints, the remaining steps in Scheme 3.2, i.e.
the fluorination of (26) and (27) with DAST and the radiolabelling step, were not yet
performed.

3.2 Labelling the 2-azido sugar (32) with aliphatic alkynes
There are several examples in the literature of click reactions of azido sugars where
the azido group is at the anomeric position, however, there are only three reported
examples of a 2-azido-2-deoxy sugar undergoing click chemistry (Fig. 3.1).
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Fig. 3.1: Examples of 2-azido sugars undergoing click chemistry.83, 84, 85

Another project within our research group, involved the development of sugar
amino acids (SAAs) bearing an azido group at C-2. Therefore, it was of interest to
extend these investigations on sugar-click chemistry to the reaction of 2-azido sugars.
As 2-azido SAAs are time-consuming to prepare, it was desirable to model the reaction
using the commercially available and simplified 2-azido sugar (32). Not only would
this be of use to other projects in the research group, but it would also add to the limited
repertoire of this type of reaction in the literature. The strategy to label the TBDMSprotected 2-azido sugar (32) is shown in Scheme 3.4.
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Scheme 3.4: A strategy to label the 2-azido sugar (32) with aliphatic alkynes.

3.2.1 Click reaction of the 2-azido sugar (32) with butynyl alcohol (4)

Scheme 3.5: The click reaction of the 2-azido sugar (32) with butynyl alcohol (4), see Table 2.2 for
reaction conditions.

Four sets of different conditions were investigated on a small-scale to optimise the
click reaction on the 2-azido sugar (32) (Scheme 3.5, Table 3.1). Reactions performed
under 80 °C and using tert-butanol proceeded but still had lots of starting material
remaining as judged by TLC (Entries 1 and 3), whereas the reaction in dichloromethane
did not proceed at all (Entry 2). The desired product was present as determined by
LRMS (ESI+) under the conditions described for Entry 1 and 3, however due to the
small scale of the reactions (around 20 mg), isolation and purification of the product
was not performed. It appears that the reaction proceeds in the presence of tert-butanol
but not in the presence of dichloromethane.
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Table 3.1: Conditions for the attempted click reaction on the 2-azido sugar (32) with butynol (4).
Entry

Solvent

Temp.
(oC)

Time
(h)

Product
detected
(LRMS)

Isolated yield
(%)

1

H2O/ t-BuOH (1:1)

40-80

24

Yes

-†

2

H2O / CH2Cl2 (1:1)

RT

24

No

-†

3

H2O/ t-BuOH / CH2Cl2
(1:1:1)

RT

24

Yes

-†

4

H2O/ t-BuOH (1:1)

80-120

72

Yes

71

† Reaction performed on small scale (< 30 mg) and therefore isolation of product not attempted.

The scale up reaction (Entry 4) afforded the novel compound (34) in a rewarding
71% yield. The product was confirmed by analysis of the 1H NMR spectrum, which
showed a new peak at

7.49 as a singlet with an integration of one proton that was

assigned to the triazole proton of (34). The formation of the triazole confirmed that the
2-azido sugar underwent a click reaction with butynyl alcohol (4). The assignment of
the 1H and

13

C NMR spectra of (34) was assisted by 2D NMR (gCOSY, gHSQC and

gHMBC). In addition, a molecular ion at, m/z 534 in the ESI mass spectrum was
assigned to the (M + Na)+ ion of (34), whereas the (M + H)+ formula, C22H38N3O9Si
confirmed by HRMS with a peak observed at 516.2371, compared to the calculated
value of 516.2377. Due to time constraints, the remaining synthetic steps in Scheme 3.4
were not pursued at this stage, but are planned for future work.
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3.3 Labelling 1- and 2-azidosugars with aromatic alkynes
Up until now, the focus has been on attaching the

18

F label through 3-

fluoropropynyl (13) and 4-fluorobutynyl (14) type residues, which both have low
boiling points of 15 oC and 45 oC respectively.63 In this section, the work was extended
to the development of other radiolabelling precursors using commercially available
alkynes of greater molecular weight and higher boiling points, such as the acetylenic
phenol (39). The proposed route for labelling 1- and 2-azido sugars with aromatic
alkynes is shown in Scheme 3.6. The acetylenic phenol (39) could be converted to the
18

F derivative using the same type of chemistry as that used in the production of the

well known imaging agent, [18F]-fluoroethyltyrosine ([18F]FET).86 The acetylenic
phenol (39) would be fluorinated using 1-tosyloxy-2-[18F]fluoroethane, then the
[18F]fluoro acetylenic phenol could be clicked to the 1- and 2-azido sugars.
The novel radiolabelled precursor (40) could then be “clicked” to 1- and 2-azido
sugars as described earlier, providing a new series of labelled compounds that are easier
to handle. The stability, ease of synthesis, yields and other parameters of the various
radiolabelled compounds could be compared to one another in order to determine the
best radiolabelling strategy for azido sugars.

Scheme 3.6: A strategy for the labelling of azido sugars via aromatic alkynes.
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3.3.1 Click reaction of 1-azidoglucuronic acid methyl ester (25) with the acetylenic
phenol (39)

Scheme 3.7: The click reaction of 1-azidoglucuronic acid methyl ester (25) with aromatic alkyne (39).

The click reaction was performed as shown in Scheme 3.7, resulting in a good yield
of (41). The reaction took around 3 h to reach completion as judged by TLC. The
product obtained after extraction appeared as a single spot on TLC, however, the NMR
spectrum of the crude product showed there were impurities. Consequently, HPLC was
used to purify the compound. During the HPLC runs the reaction mixture precipitated
several times, which could be avoided by adding dimethylformamide.
The product (41) was obtained as an isomeric mixture in the ratio 3:1 under the
conditions described in Scheme 3.7. Presumably these are

/ -anomers rather than

1,4/1,5-regiosiomers due to the large chemical shifts differences observed for the
protons on the sugar ring (e.g. 6.43 and 6.21 ppm for the major and minor H1 proton,
respectively). In contrast, under the conditions described in Scheme 3.3, the same
starting material (25), gave a single product. Analysis of the 1H NMR spectra of the
product showed a peak at
another at

7.28 as a multiplet with an integration of three protons and

6.75 as a multiplet with an integration of one proton, which were assigned

to the four protons in the aromatic ring. A one proton singlet at

8.94/ 8.82∗ was

assigned to the triazole proton, confirming the production of compound (41). The 2D
NMR derived from gCOSY and gHSQC were used in assisting the assignment of the
1

H and 13C NMR spectra of the desired compound.

∗

Belongs to the minor isomer.
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In addition, the ESI+ mass spectrum of the phenol product (41), a peak at, m/z
500.3, was assigned to the (M + Na)+ ion. Furthermore, the (M + H)+ formula of
C21H24N3O10 was confirmed by HRMS with a peak at, m/z 478.1481 compared to the
calculated value of 478.1462. The fluoroethylation of (41) could not be performed due
to time constraints, but is planned for future work.
3.3.2

Click reaction of 1-azidoglucosamine (2) with the acetylenic phenol (39)

Scheme 3.8: Click reaction of 1-azido glucosamine with the aromatic alkyne (39).

Preparation of the phenolic triazole sugar (42) provides another useful example to
add to the existing library of click reactions on anomeric azido sugars. The click
reaction of the 1-azidoglucosamine (2) with the aromatic alkyne (39) was performed as
shown in Scheme 3.8. The reaction took 2.5 h to reach completion, after which the
reaction mixture was filtered and purified by HPLC. Analysis of the 1H NMR and 13C
NMR spectra confirmed the isolation of the product (42), where peaks at

H

8.74 and

C

120.3 were assigned to the triazole proton and triazole carbon respectively. The four
protons of the aromatic ring were assigned to peaks at

7.25, which appeared as a

multiplet with an integration of three, and a peak at

8.11 as a doublet with an

integration of one proton. The broad singlet at

9.60 with an integration of one proton

was assigned to the hydroxyl proton. The 2D NMR on related compounds (e.g. gCOSY
data of (5) and gHSQC of (41) were used to assist in the assignment of the 1H and 13C
NMR spectra of (42).
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In addition, a base peak at, m/z 513 in the ESI+ mass spectrum was assigned to the
(M + Na)+ ion of the phenol product (42), with the (M + Na)+ formula of
C22H26N4O9Na confirmed by HRMS with a peak at, m/z 513.1586 compared to the
calculated value of 513.1597. Again, due to time constraints, the remaining steps in
Scheme 3.6, i.e. fluoroethylation of (42) and the click reaction of 2-azido sugar (32)
with the aromatic alkyne (39), remain for future work.
In conclusion, this chapter has described the development of a new method for
radiolabelling various carbohydrates for use in PET imaging through the utilisation of
click chemistry. We have shown that the click reaction is very useful and easy to
perform under mild conditions to conjugate various alkynes with 1- and 2-azido sugars.
The method developed here could be used to radiolabel various azido sugars, including
the SAAs and SDAs, which are in development within our research group. These
radiolabelled sugars have the potential to become key building blocks in the
development of improved peptidomimetic imaging agents.
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Chapter 4: Conclusions and Future Directions

4.1 Conclusions
PET imaging of tumours is important because it is a non-invasive functional
imaging modailty which can provide information not only about the location of the
disease but also about how the target area (organ) is functioning. PET imaging offers an
advantage by employing positron emitting isotopes of carbon, oxygen and nitrogen,
which are the main elements of bioorganic molecules.
Herein we have described our development of a new method for radiolabelling
various carbohydrates for use in PET imaging through the utilisation of click chemistry.
Our work resulted in the generation of eight new carbohydrate derivatives including the
novel [18F]-labelled glucosamine derivative (12). This radiolabelled sugar contains a
NHAc group at C-2, which upon liberation of the free amine can be coupled via
standard peptide coupling methods to various bioactive peptides used in cancer imaging
such as the integrin antagonist cyclo-RGD (see Fig. 2. 1).
As described in Chapter 2, the click reaction using CuSO4/ Na ascorbate as catalyst,
in the tert-butanol/water gave a good yield of the desired hydroxymethyl triazole sugar
(5) and novel hydroxyethyl triazole sugar (6). The synthesis of the known
hydroxymethyl compound (5) afforded the compound in 74% yield after 2 hours, a
significant improvement over the corresponding literature reaction, which resulted in
62% yield after 3 hours. The hydroxy triazoles (5) and (6) were then successfully
fluorinated to afford the novel fluoromethyl and fluoroethyl triazole sugars (7) and (8)
respectively, as standards for the radiolabelling and purification of the target compound
[18F]-labelled glucosamine (12). The radiolabelling of [18F]-labelled glucosamine (12)
using 4-[18F]fluoro-1-butyne was successfully accomplished in 8 min, therefore we
demonstrated that click chemistry can be used to prepare the radiolabelled

18

F-

compounds efficiently and rapidly (Scheme 4.1).
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Scheme 4.1: Reagents and conditions: a) CuSO4.H2O, Na ascorbate, t-BuOH/ H2O, RT, 2h, 74% yield (n
= 1), 94% yield (n = 2); b) DAST, DCM, 30- 45 mins, 33% yield (n = 1), yield 30% (n = 2); c)
CuSO4.H2O, Na ascorbate, DIPEA / H2O , 90 0C, 8 min, 22% radiochemical yield, 80% radiochemical
purity.

As described in Chapter 3, this work was then extended to the click reaction of 1azidoglucuronic acid methyl ester (25) to afford the glucuronide hydroxymethyl and
hydroxyethyl triazole sugars (26) and (27) in moderate to good yields. The two novel
glucuronide triazoles (26) and (27) added yet more examples of novel sugar-click
derivatives. Furthermore, after deprotection, they can be potentially conjugated to
peptides through the carboxylic acid at C-6 ( Scheme 4.2).

Scheme 4.2: The click reaction of 1-azido glucuronide (25) with alkynols (3) and (4).
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The click reaction of the 2-azido sugar (32) gave a high yield of the novel 2-azido
triazole sugar (34) and widened the scope of click reactions on 2-azido sugars, of which
only a few examples have been reported in the literature (Scheme 4.3).

Scheme 4.3: Click reaction on 2-azido sugar.

The click reaction on 1-azido glucosamine (2) and 1-azidoglucuronic acid methyl
ester (25) with the acetylenic phenol (39) gave the novel glucuronic and glucosamine
phenol triazole sugars (41) and (42) respectively in good yields. These compounds
containing an aromatic phenol can be potentially F-18 labelled using the same method
as in the radiolabelling of the well known imaging agent [18F]FET (Scheme 4.4).

Scheme 4.4: A strategy for the radiolabelling of 1-azido sugar (2) and 1-azido glucuronide (25) using
[18F]FET technology.

The work described in this thesis is part of an on-going project in our research
group aimed at improving existing imaging agents as well as the development of new
types of imaging compounds. The click-based methodology developed and described
here has significant potential for use in labelling bioactive peptides in the future.

48

Chapter 4: Conclusions and Future Directions

4.2 Future directions
There is considerable scope for more research work to be undertaken in this
project. The hydroxymethyl and hydroxyethyl triazole sugars (5) and (6) could be
coupled to bioactive peptides such as cyclo RGD and radiolabelled using the methods
described previously (see Section 2.1). After which, binding studies to αvβ3-integrin in
U87 cells then could be performed to assess how the addition of the sugar triazole
affects integrin binding. There is potential here for the generation of a new integrin
antagonist type imaging agent. Preparation of the radiolabelled fluoromethyl triazole
sugar (11) could also be undertaken, however, the low boiling point (15 oC) properties
of the propargyl fluoride (13) do present challenges.
In order to complete the preparation of the radiolabelled 1-azidoglucuronic
derivatives (30) and (31), fluorination of the compounds (26) and (27) could be
performed to obtain the cold standards for HPLC, followed by the radiolabelling of (25)
using the method described previously. Likewise, for the preparation of the
radiolabelled 2-azido sugar derivatives (34), fluorination could be performed on
compound (34) in order to obtain the cold standard. The click reaction also could be
performed on the 2-azido sugar (32) with propargyl alcohol (3) to provide another
example of a 2-azido sugar triazole derivative.
In order to complete the preparation of the radiolabelled 1- and 2-azido sugar
derivatives with the acetylenic phenol (39), fluoroethylation is needed to obtain the cold
standards for compounds (41) and (42). After that, the preparation of the radiolabelled
phenol could be attempted using the same methods as in the preparation of [18F]FET,
and the radiolabelled aromatic alkyne ‘clicked’ with the various azido sugars.
Considerable scope still remains in the optimisation of the parameters (such as time and
temperature)

for

all

of

the

reactions

to

obtain

even

better

results.
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Chapter 5: Experimental
5.1 General comments
Chemicals and solvents were obtained from Sigma – Aldrich Chemical Co. unless
otherwise noted and used without further purification. All reactions were performed in
standard glassware. Solvent removal was performed using a Buchi rotary evaporator at
temperatures not greater than 60 oC. The 1-azido sugars (2) and (25) were purchased
from Carbosynth Limited. The 2-azido sugar (32) was purchased from Sigma Aldrich.
Melting points were recorded on an Optimelt-Automated Melting Point System, Digital
Image Processing Technology apparatus. Temperatures are reported in degrees Celsius
(oC) and are uncorrected. Fluorine-18 [18F]HF was produced on a GE PET trace
Cyclotron via the 18O(p, n)18F nuclear reaction (Cyclotek, Australia). F-18 fluorination
reactions were carried out in the presence of potassium carbonate and the amino
polyether Kryptofix2.2.2. in acetonitrile under nitrogen.

Nuclear magnetic resonance (NMR) spectroscopy
Proton (1H) nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz
on a Bruker NMR spectrometer. Spectra were recorded in deuterated chloroform
(CDCl3), using chloroform (

7.26), TMS (

deuterated dimethyl sulfoxide (DMSO-d6,

0.00) as the internal standards and

2.50). Chemical shifts ( ) were measured

in parts per million (ppm). Multiplicities were reported as singlet (s), doublet (d),
doublet of doublets (dd), triplet (t), doublet of triplets (dt), quartet (q), and multiplet
(m). Coupling constants (J) are reported in Hertz. Hydrogen and carbon assignments
were also made using standard gradient correlation spectroscopy (gCOSY), gradient
heteronuclear single quantum correlation (gHSQC) and gradient heteronuclear multiple
bond correlation (gHMBC) spectroscopic techniques.
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Mass spectrometry
Low resolution mass spectra (LRMS) were obtained using a Waters Micromass ZQ
quadropole Mass Spectrometer and high resolution mass spectra (HRMS) were
obtained on a Micromass QTOF2 ultima mass spectrometer.

Chromatography
Thin layer chromatography (TLC) was performed on Merck F254 silica plates.
Detection was done under UV light and with 5% H2SO4 in ethanol for sugar containing
compounds. Gravity column chromatography was performed using Merck silica gel,
grade 60, 70-230 mesh, 60Å. The solvent used in individual chromatographic
experiments is indicated and eluents are expressed as volume: volume (v:v)
proportions.
The [18F] radiolabelled products were assessed and purified by high performance
liquid chromatography (HPLC), consisting of a Waters 600 Controller, Waters 515
HPLC pump and Waters in line degasser AF, λ= 226 nm. A Linear UV is detector (λ =
254 nm) was used in series with a Carroll and Ramsey model 105S gamma detector, on
a Phenomenex Bondclone C18 column (300 x 7.8 mm, 10 µm) at 4 ml/min with 20%
ACN, 80% H2O and 0.1% TFA as the mobile phase. The identity of the labelled
compounds was confirmed by co-injection with the authentic compounds on the above
HPLC system. Radioactivity was measured with a Capintec R15C dose calibrator.
For compound (40) and (41), HPLC was performed on a semi-preparative RP
Altima C18 250 x 22 mm column using a Waters 771 plus Auto sampler, Waters pump
Prep LC Controller and WatersTM 486 Tunable Absorbance detector set at 210 nm.
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5.2 Chemical synthesis
1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-4-(hydroxymethyl)1,2,3-triazole (5)
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-

OAc
AcO
AcO

O
NHAc

N N
N

OH

glucopyranosyl azide (400 mg, 1.08 mmol) and
propargyl alcohol (63.0 µl, 1.08 mmol) were added

to a solution of CuSO4.5H2O (55.0 mg, 0.22 mmol) and sodium ascorbate (86.0 mg,
0.43 mmol) in a 1:1 mixture of tert-butanol / water (6 ml). The reaction mixture was
stirred for 2 h at RT and then extracted with ethyl acetate (3 x 20 ml). The organic
extracts were combined, dried over anhydrous Na2SO4, and concentrated under reduced
pressure. The extraction afforded 5 as a white solid (340 mg, 74%), m.p. 146-148 oC,
(note that the melting point of this known compound is not reported in the literature 76).
Rf 0.56 (silica, 9:1, DCM : MeOH). Spectral and physical data for compound 5 were
identical to those reported.76
1

H-NMR (CDCl3) 1.76 (s, 3H, NHAc), 2.04 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.67

(OH), 2.10 (s, 3H, OAc), 4.01 (m, 1H, H-5), 4.14 (dd, 1H, J = 12.5 Hz, 2.0 Hz, H-6a),
4.28 (dd, 1H, J = 12.6 Hz, 4.9 Hz, H-6b), 4.62 (q, 1H, J = 10.1 Hz, H-2), 4.80 (s, 2H,
CH2OH), 5.28 (t, 1H, J = 9.8 Hz, H-4) 5.47 (t, 1H, J = 10.0 Hz, H-3), 6.03 (d, 1H, J =
9.9 Hz, H-1), 6.23 (d, 1H, J = 9.0 Hz, NHAc), 7.83 (s, 1H, H-triazole). MS: LRMS m/z
(ES+) 451.1 (M + Na)+.

1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-4-(hydroxyethyl)1,2,3-triazole (6)
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-

OAc
AcO
AcO

O
NHAc

N N
N

glucopyranosyl azide (400 mg, 1.08 mmol) and
OH
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butynyl alcohol (82.0 µl, 1.08 mmol) were added to a solution of CuSO4.5H2O (55.0
mg, 0.22 mmol) and sodium ascorbate (86.0 mg, 0.43 mmol) in a 1:1 mixture of tertbutanol/water (6 ml). The reaction mixture was stirred for 2 h at RT and then extracted
with ethyl acetate (3 x 20 ml) The organic extracts were combined, dried over
anhydrous Na2SO4, and concentrated under reduced pressure. The extraction afforded 6
(450 mg, 94%) as a white solid, m.p. 180-184 oC, Rf 0.6 (silica, 20:1, DCM : MeOH).
1

H-NMR (CDCl3) 1.74 (s, 3H, NHAc), 2.07 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.09 (s,

3H, OAc), 2.98 (m, 2H, CH2CH2OH), 3.89 (m, 2H, CH2OH), 4.11 (m, 1H, H-5), 4.18
(dd, 1H, J = 12.6 Hz, 2.2 Hz, H-6a), 4.33 (dd, 1H, J = 12.6 Hz, 4.9 Hz, H-6b), 4.63 (q,
1H, J = 9.8 Hz, H-2), 5.28 (t, 1H, J = 9.7 Hz, H-4) 5.53 (t, 1H, J = 9.4 Hz, H-3), 6.08
(d, 1H, J = 9.8 Hz, H-1), 7.13 (d, 1H, J = 9.1 Hz, NHAc), 7.88 (s,1H, H-triazole). (1H,
OH is not observed in the spectrum).

13

C-NMR (CDCl3)

20.6 (OAc), 20.7 (OAc),

20.7 (OAc), 22.7 (NHAc), 29.2 (CH2CH2OH), 53.8 (C-2), 61.4 (CH2OH), 61.8 (C-6),
68.2 (C-4), 72.2 (C-3), 74.9 (C-5), 86.2 (C-1), 121.5 (CH-triazole), 145.9 (C triazole),
169.4 (C=O), 170.7 (C=O), 170.8 (C=O), 171.2 (C=O). MS: LRMS m/z (ES+) 465 (M
+ Na)+. . HRMS calculated for C18H26N4O9Na: 465.1597, found 465.1596 .

1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-4-(fluoromethyl)
1H-1,2,3-triazole (7)
DAST (69 µl, 0.52 mmol) was added to hydroxyl

OAc
AcO
AcO

O
NHAc

N N
N

F

sugar 5 (150 mg, 0.35 mmol) dissolved in 4.5 ml of
dichloromethane and the reaction mixture was stirred

for 30 min at 0 oC. Sodium hydrogen carbonate was added and then the reaction
mixture was extracted with dichloromethane (3 x 20 ml). The organic extracts were
combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The
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product was purified using gravity column chromatography on silica gel (DCM:
MeOH, 18:1) to afford 7 (50 mg, 33%) as a light brown solid, m.p. 198-203 oC, Rf 0.5
(silica, 10:1, DCM : MeOH).
1

H-NMR (CDCl3)

1.79 (s, 3H, NHAc), 2.08 (s, 6H, OAc), 2.09 (s, 3H, OAc),

4.06 (m, 1H, H-5), 4.16 (dd, 1H, J = 12.5 Hz, 2.1 Hz, H-6a), 4.30 (dd, 1H, J = 12.6 Hz,
5.0 Hz, H-6b), 4.66 (q, 1H, J = 10.1 Hz, H-2), 5.28 (t, 1H, J = 9.5 Hz, H-4), 5.51 (t, 1H,
J = 9.2 Hz, H-3), 5.49 (d, 2H, J = 48 Hz, CH2F), 6.09 (d, 1H, J = 9.8 Hz, H-1), 6.63 (bs,
1H, NHAc), 8.03 (s, 1H, H-triazole). 13C-NMR (CDCl3)

20.5 (OAc), 20.5 (OAc),

20.6 (OAc), 22.7 (NHAc), 53.4 (C-2), 61.6 (C-6), 67.9 (C-4), 72.1 (C-3), 74.6 (CH2F),
76.1 (C-5), 85.8 (C-1), 123.1 (CH-triazole), 143.1 (C triazole), 143.3 (C=O), 169.2
(C=O), 170.5 (C=O) 170.7 (C=O) MS: LRMS m/z (ES+) 453.1 (M + Na)+. HRMS
calculated for C17H23N4O8NaF: 453.1398, found 453.1393.

1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-4-(2-fluoroethyl)1H-1,2,3-triazole (8)
Compound 8 was synthesized using the same

OAc
AcO
AcO

O

N N
N

NHAc

procedure to produce 7. DAST (45 µl, 0.34 mmol)
F

was added to the hydroxyl sugar 6 (100 mg, 0.23

mmol) which was dissolved in 3 ml of dichloromethane and the reaction mixture was
stirred for 45 min at 0 oC. Sodium hydrogen carbonate was added and then the reaction
mixture extracted with dichloromethane (3 x 20 ml). The organic extracts were
combined, dried over Na2SO4, and concentrated under reduced pressure. The product
was purified using gravity column chromatography on silica gel (DCM : MeOH, 99 :1)
to afford 8 (30 mg, 30%) as a light brown solid, 155-161 oC, Rf 0.6 (silica, 12:1, DCM:
MeOH).
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1

H-NMR (CDCl3)

1.76 (s, 3H, NHAc), 2.06 (s, 6H, OAc), 2.07 (s, 3H, OAc), 3.15

(dt, 2H, J = 25.0 Hz, 6.1 Hz, CH2CH2F), 4.03 - 4.07 (m, 1H, H-5), 4.15 (dd, 1H, J =
12.6 Hz, 2.1 Hz, H-6a), 4.29 (dd, 1H, J = 12.6 Hz, 4.8 Hz, H-6b), 4.62 (q, 1H, J = 9.8
Hz, H-2), 5.26 (t, 1H, J = 10.0, H-4) 5.54 (t, 1H, J = 9.4 Hz, H-3), 4.70 (dt, 2H, J = 46.9
Hz, 6.1 Hz, CH2F) 6.1 (d, 1H, J = 10.0 Hz, H-1), 6.8 (d, 1H, J = 9.3 Hz, NHAc), 7.88
(s,1H, H-triazole).

13

C-NMR (CDCl3)

20.5 (OAc), 20.6 (OAc), 20.6 (OAc), 22.7

(NHAc), 27.3 (CH2CH2F), 53.2 (C-2), 64.9 (CH2F), 72.3 (C-6), 74.7 (C-4), 81.3 (C-3),
83.0 (C-5), 85.7 (C-1), 121.3 (CH-triazole), 143.8 (C triazole), 143.9 (C=O), 169.3
(C=O), 170.5 (C=O), 170.6 (C=O). MS: LRMS m/z (ES+) 467.1 (M + Na)+, HRMS
calculated for C18H25N4O8NaF: 467.1554, found 467.1577.

Attempted

synthesis

of

(1-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-

glucopyranosyl)-1H-1,2,3-triazol-4-yl)methyl 4-methylbenzenesulfonate (9)

Method A - Tosylation of hydroxyl sugar (5)
1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-1H-1,2,3-triazol4yl)methanol (5) (100 mg, 0.23 mmol) was dissolved in anhydrous dichloromethane
(3ml) and triethyl amine (190 µl, 1.35 mmol) was added to the solution. The solution
was stirred for 1 hr before the addition of tosyl chloride (90.0 mg, 0.45 mmol) and then
stirred for another 3 h at 0 oC. The reaction mixture was extracted with dichloromethane
(3 x 20 ml) and the organic extracts were combined, dried over Na2SO4 and the solvent
evaporated to yield a white powder (190 mg). TLC analysis indicated the formation of a
single product for which 1H NMR spectral analysis showed the presence of the aromatic
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ring of the tosylate group and triethyl amine peaks, but none of the carbohydrate
protons were detected. Re-extraction of the aqueous layer with ethyl acetate and
washing with sodium bicarbonate and brine afforded 30 mg of crude product, which
was found by LRMS (ESI+) to produce a peak at 605 (M + Na+) consistent with that of
the desired compound (9). Due to the low yield, the product was not further isolated and
purified.

Method B - Tosylation of hydroxyl sugar (5)
1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-1H-1,2,3-triazol-4yl)methanol (5) (50 mg, 0.12 mmol) was dissolved in anhydrous dichloromethane
(1.5ml). Triethyl amine (17.0 µl, 0.12 mmol) was added to the solution, which was
stirred for 1 h before tosyl chloride (46.0 mg, 0.24 mmol) was added. The reaction
mixture was stirred for a further 3 hrs at 0 oC and then left in the fridge overnight. TLC
analysis of the reaction mixture showed several by-products and LRMS (ESI+) did not
show the presence of the desired compound (9).

Method C – Click reaction of azido sugar (2) with tosylated alkyne (20)
1-Azido glucosamine (2) (150 mg, 0.40 mmol) and propargyl tosylate (20) (84.1 mg,
0.40 mmol) were added to a solution of CuSO4.5H2O (20.0 mg, 0.08 mmol) and
sodium ascorbate (31.7 mg, 0.16 mmol) in a 1:1 mixture of tert-butanol/water (3 ml).
The reaction mixture was stirred at RT for 2 h and then left overnight in the fridge. The
reaction mixture was extracted with ethyl acetate (3 x 20 ml) and the combined organic
extracts dried over Na2SO4, and the solvent evaporated. TLC analysis showed the
starting material was completely consumed but the NMR of the crude product showed
that the azide (2) and the alkyne (3) had not undergone a click reaction.
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Attempted

synthesis

of

2-(1-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-

glucopyranosyl)-1H-1,2,3-triazol-4-yl)ethyl 4-methylbenzenesulfonate (10)
The attempted synthesis of (10) utilised the same
AcO
AcO

OAc
O

conditions as those described in the attempted

N N
N
NHAc

OTs

synthesis of (9) (method C). 1-Azido glucosamine

(2) and butynyl tosylate (4) (89.8 mg, 0.40 mmol) were added to a solution of
CuSO4.5H2O (20.0 mg, 0.08 mmol) and sodium ascorbate (31.7 mg, 0.16 mmol) in a
1:1 mixture of tert-butanol/water (3 ml). The reaction mixture was stirred at RT for 2 h
and was left overnight in the fridge. The reaction mixture was then extracted with ethyl
acetate (3 x 20 ml), the combined organic extracts dried over Na2SO4, and the solvent
evaporated. TLC analysis of the crude material showed that the starting material was
completely consumed but the NMR of the crude product showed that the azide (6) and
alkyne (4) had not undergone a click reaction.

2-Propynyl-4-methylbenezene sulfonate (propargyl tosylate) (20)
O
O S
O

To a solution of propargyl alcohol (2.10 g, 0.03 mol) in dry
CH3

dichloromethane (150 ml), triethylamine (3.03 g, 0.03 mol)

was added and the mixture stirred for 1 h at RT. Tosyl chloride (11.4 g, 0.06 mol) was
then added and the mixture stirred for a further 3 h at 0 oC. After the addition of water
(50 ml), the mixture was extracted with dichloromethane (5 x 30 ml), washed with
water, dried over Na2SO4, filtered and evaporated. The product was purified using
gravity column chromatography on silica gel (ethyl acetate: petroleum ether, 20:80) to
afford 20 (4.04 g, 54%) as light dark oil. Rf 0.13 (silica, petroleum ether: ethyl acetate,
9:1). Spectral and physical data for compound 20 were identical to those reported.81
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1

H-NMR (CDCl3)

2.46 (s, 3H, CH3), 2.52 (s, 1H, CH), 4.70 (s, 2H, CH2O), 7.36 (d,

J = 8.4 Hz, 2H, ArH), 7.80 (d, J = 8.4 Hz, 2H, ArH). MS: LRMS m/z (ES+) 232.9 (M +
Na)+.

3-Butynyl-4-methylbenezene sulfonate (butynyl tosylate) (21)
The 3-butynyl-4-methylbenezene sulfonate (butynyl

O
O S
O

CH 3

tosylate) 21 was synthesized according to the same

procedure used to produce 20. A solution of 3-butyn-1-ol (2.00 g, 0.04 mol) and
triethylamine (3.61 g, 0.04 mol) dissolved in dry dichloromethane (150 ml), was stirred
for 1 h at RT. Tosyl chloride (13.53 g, 0.07 mol) was added and the mixture stirred for
another 3 h at 0 oC. After the addition of water (50 ml), the mixture was extracted with
dichloromethane (5 x 30ml), washed with water, dried over Na2SO4, filtered and
evaporated. The product was purified using gravity column chromatography on silica
gel (ethyl acetate: petroleum ether, 20:80) to afford 21 (6.13 g, 91.07%) as an oil. Rf
0.36 (silica, petroleum ether: ethyl acetate, 9:1). Spectral and physical data for
compound 21 were identical to those reported.63
1

H-NMR (CDCl3) 1.97 (s, 1H, CH), 2.46 (s, 3H, CH3), 2.56 (m, 2H, CH2CH2O), 4.13

(m, 2H, CH2CH2O), 7.35 (d, J = 8.6 Hz, 2H, ArH), 7.81 (d, J = 8.4 Hz, 2H, ArH). MS:
LRMS m/z (ES+) 247.1 (M + Na)+ .

Attempted

synthesis

of

1-(2-acetamido-2-deoxy- -D-glucopyranosyl)-4-

(fluoromethyl)-1H-1,2,3-triazole (23)

HO
HO
AcHN

OH
ON N
N

This reaction was performed according to a literature
F

method.63 To the crude fluoromethyl triazole sugar (7)

(100 mg, 0.23 mmol) in acetonitrile (2 ml), sodium methoxide (0.5 M in ACN, 120 µl,
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0.06 mmol) was added and the reaction mixture stirred at RT for 30 min. The reaction
mixture was then neutralized by stirring with Amberlite IR-120 acidic ion-exchange
resin for 30 min. Filtration of the resin followed by removal of the solvents under
reduced pressure gave 30 mg of crude product. The formation of the desired product
was observed by LRMS (ESI+) with a peak at, m/z = 327 corresponding to (M + Na)+
for (23), however the isolation and further characterisation of the compound was not
performed due to the low yield of product and complex mixture of side products.

Attempted

synthesis

of

1-(2-acetamido-2-deoxy- -D-glucopyranosyl)-4-(2-

fluoroethyl)-1H-1,2,3-triazole (24)
As described above, the crude fluoroethyl triazole sugar
HO
HO
AcHN

OH
ON N
N

F

(8) (100 mg, 0.23 mmol) was dissolved in ACN (2ml), and
to this was added sodium methoxide (0.5 M in ACN, 120 µl,

0.06 mmol). The reaction mixture was worked up as described for (7) to give 30 mg of
the crude product. Again, the TLC analysis showed the presence of several products.
Analysis of the crude mixture by LRMS (ESI+) revealed the presence of a peak at, m/z
= 341 (M + Na)+ consistent with that of the desired compound (24), however, the
product isolation and further characterisation were not performed due to the low yield
of product and complex mixture of side products.

(1-(Methyl 2,3,4-tri-O-acetyl- -D-glucuronide)-1H-1,2,3-triazole-4-yl)methanol (26)
H 3CO
AcO
AcO

1-Azido-2,3,4-tri-O-acetyl- -D-glucuronide methyl

O
O

N N
N

OAc

OH

ester (150 mg, 0.42 mmol) and propargyl alcohol
(24.4 µl, 0.42 mmol) were added to a solution

ofCuSO4.5H2O (21.0 mg, 0.08 mmol) and sodium ascorbate (33.3 mg, 0.17 mmol) in a
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1:1 mixture of tert-butanol/water (3 ml). The reaction mixture was stirred for 48 h at
RT. TLC (10: 90, MeOH: CHCl3) showed minimal product had formed so another 0.2
equivalents of CuSO4.5H2O (21 mg, 0.08 mmol) was added to accelerate the reaction
and the mixture was stirred at RT for another 24 h. The reaction was then extracted
with ethyl acetate (2 x 20 ml). The organic extracts were combined, dried over
anhydrous Na2SO4, and concentrated under reduced pressure. The resulting solid was
purified by gravity column on silica gel (1-5% MeOH: DCM) to yield 26 (40 mg, 23%)
as a white solid, m.p.187-190 oC, Rf 0.4 (silica, 90:10, CH2Cl3: MeOH).
1

H-NMR (CDCl3)

1.87 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.50 (bs,

1H, OH), 3.74 (s, 3H, CO2CH3), 4.34 (d, 1H, J = 9.9 Hz, H-5), 4.79 (s, 2H, CH2OH),
5.37 (m, 1H, H-2), 5.46-5.49 (m, 2H, H-3, H-4), 5.93 (d, 1H, J = 9.1 Hz, H-1), 7.86 (s,
1H, H-triazole).

13

C-NMR (CDCl3)

20.3 (OAc), 20.5 (OAc), 20.6 (OAc), 53.3

(CO2CH3), 56.6 (CH2OH), 69.1 (C-4), 70.2 (C-2), 72.0 (C-3), 75.0 (C-5), 85.6 (C-1),
120.4 (CH-triazole), 147.6 (C-triazole), 166.3 (C=O), 169.1 (C=O), 169.5 (C=O), 169.8
(C=O). MS: LRMS m/z (ES+) 438.3 (M + Na)+. HRMS calculated for C16H22N3O10:
416.1305 found 416.1305 (M + H)+.

(1-(Methyl 2,3,4-tri-O-acetyl- -D-glucuronide)-1H-1,2,3-triazole-4-yl)ethanol (27)
H3 CO
AcO
AcO

1-Azido-2,3,4-tri-O-acetyl- -D-glucuronide

O
O
OAc

N N
N

methyl ester (150 mg, 0.42 mmol) and butynyl
OH

alcohol (31.8 µl, 0.42 mmol) were added to a

solution of CuSO4.5H2O (21.0 mg, 0.08 mmol) and sodium ascorbate (33.3 mg, 0.17
mmol) in a 1:1 mixture of tert-butanol/water (3 ml). The reaction mixture was stirred
overnight at RT and then extracted with ethyl acetate (2 x 20 ml). The organic extracts
were combined, dried over anhydrous Na2SO4, and concentrated under reduced
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pressure. The extraction afforded 27 (150 mg, 83%) as a white solid, m.p. 179-181 oC,
Rf 0.4 (silica, 90:10, CH2Cl3: MeOH).
1

H-NMR (CDCl3)

1.88 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.96 (bs,

2H, CH2CH2OH), 3.76 (s, 3H, CO2CH3), 3.92 (bs, 2H, CH2OH), 4.35 (d, 1H, J = 9.8
Hz, H-5), 5.34-5.44 (m, 2H, H-4, H-3) 5.47-5.52 (m, 1H, H-2) 5.92 (d, 1H, J = 9.1 Hz,
H-1), 7.74 (s, 1H, H-triazole), (1H, OH is not observed in the spectrum).
(CDCl3)

13

C-NMR

20.1 (OAc), 20.4 (OAc), 20.5 (OAc) 28.8 (CH2CH2OH), 53.1 (CO2CH3),

61.4 (CH2OH), 69.0 (C-4), 70.3 (C-2), 71.7 (C-3), 74.9 (C-5), 85.5 (C-1), 120.4 (CHtriazole), 146.4 (C-triazole), 166.2 (C=O), 169.1 (C=O), 169.3 (C=O), 169.7 (C=O).
MS: LRMS m/z (ES+) 452.2 (M + Na)+ . HRMS calculated for C17H24N3O10: 430.1462
found 430.1451 (M + H)+.

(1-(1-O-Tert-butyldimethylsilyl-2-deoxy- -D-glucopyranosyl-3,4,6-tri-O-acetyl)1H-1,2,3-triazol-4-yl)ethanol (34)

AcO
AcO

1-O-Tert-butyldimethylsilyl-2-azido-2-deoxy- -D-

OAc
O

glucopyranoside-3,4,6-triacetate (200 mg, 0.44 mmol)
OTBDMS

N N
N

and butynyl alcohol (40 µl, 0.53 mmol) were added to a
solution of CuSO4.5H2O (22.0 mg, 0.09 mmol) and

HO

sodium ascorbate (35.7 mg, 0.18 mmol) in a 1:1

mixture of tert-butanol/water (3 ml). The reaction mixture was stirred for 3 days at 80120 oC and then extracted with ethyl acetate (2 x 20 ml). The organic extracts were
combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The
product was purified using gravity column chromatography on silica gel (1-5% MeOH:
DCM) to afford 34 (160 mg, 71%) as a brown thick oil, Rf 0.4 (silica, 16: 1, DCM:
MeOH).
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1

H-NMR (CDCl3)

-0.14 (s, 3H, SiCH3), -0.05 (s, 3H, SiCH3), 0.67 (s, 9H,

(SiC(CH3)3), 1.76 (s, 3H, OAc) 1.98 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.86 (t, 2H, J =
6.1 Hz, CH2CH2OH) 3.84 (t, 2H, J = 6.0 Hz, CH2OH), 3.90-3.93 (m, 1H, H-5), 4.10
(dd, 1H, J = 12.1 Hz, 2.2 Hz, H6a), 4.22-4.32 (m, 2H, H-6b, H-2), 5.06 (t, 1H, J = 9.6
Hz, H-4), 5.15 (d, 1H, J = 7.7 Hz, H-3) 5.81 (t, 1H, J = 9.2 Hz, H-1), 7.41 (s, 1H, Htriazole), (1H, OH is not observed in the spectrum). 13C-NMR (CDCl3)

-4.7 (SiCH3),

-5.8 (SiCH3), 17.7 ((SiC(CH3)3), 20.3 (OAc), 20.6 (OAc), 20.7 (OAc), 25.2
(SiC(CH3)3), 28.6 (CH2CH2OH), 61.5 (CH2OH), 62.3 (C-6), 66.1 (C-2), 69.3 (C-4),
71.9 (C-3), 72.0 (C-5), 95.8 (C-1), 123.4 (CH-triazole), 144.9 (C-triazole), 169.4
(C=O), 169.8 (C=O), 170.6 (C=O). MS: LRMS m/z (ES+) 538.4 (M + Na)+. HRMS
calculated for C22H38N3O9Si: 516.2377 found 516.2371 (M + H)+.

3-(1-(Methyl 2,3,4-tri-O-acetyl- -D-glucuronide)-1H-1,2,3-triazol-4-yl)phenol (41)
H3 CO
AcO
AcO

1-Azido-2,3,4-tri-O-acetyl- -D-glucuronide

O
O
OAc

N N
N

OH

methyl ester (200 mg, 0.60 mmol) and phenol
39 (56.3 µl, 0.86 mmol) were added to a

solution of CuSO4.5H2O (27.5 mg, 0.11 mmol) and sodium ascorbate (45.6 mg, 0.23
mmol) in a 1:1 mixture of tert-butanol/water (3 ml). The reaction mixture was stirred 3
h at RT and then extracted with ethyl acetate (2 x 20 ml). The organic extracts were
combined, dried over anhydrous Na2SO4, concentrated under reduced pressure and then
purified using HPLC (RP Altima C18 column, flow rate = 50-300 mL/min, isocratic
run 40% ACN, 50% H2O, 10% NH4HCO3, tR = 18.4 min) to afford 41 (180 mg, 66%)
as a white solid, m.p. 198-200 oC, Rf 0.4 (silica, 1:20, MeOH : DCM).
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1

H-NMR (DMSO-d6)

1.81 (s, 3H, OAc), 2.00 (s, 3H, OAc), 2.03 (s, 3H, OAc), 3.65

(s, 3H, CO2CH3), 4.84/4.1∗ (d, 1H, J = 10.0 Hz, H-5), 5.23 (m, 1H, H-2), 5.67/5.43* (t,
1H, J = 9.4 Hz, H-4), 5.78/5.58* (t, 1H, J = 9.3 Hz, H-3), 6.43/6.21* (d, 1H, J = 9.2 Hz,
H-1), 6.75 (m, 1H, ArH), 7.26 (m, 3H, ArH), 8.94/8.82* (s, 1H, H-triazole). (1H, OH is
not observed in the spectrum). 13C-NMR (DMSO-d6)

19.9 (OAc), 20.2 (OAc), 20.3

(OAc), 52.7 (CO2CH3), 68.5 (C-4), 69.9 (C-2), 71.5 (C-3), 72.9 (C-5), 83.9 (C-1),
112.1 (ArCH), 115.5 (ArC), 116.1 (ArCH), 120.5 (CH-triazole), 130.1 (ArCH), 131.1
(ArCH), 147.2 (C-triazole), 157.9 (ArCOH), 166.6 (C=O), 168.9 (C=O), 169.4 (C=O),
169.6 9 (C=O). MS: LRMS m/z (ES+) 500.3 (M + Na)+. HRMS calculated for
C21H24N3O10: 478.1462 found 478.1481 (M + H)+.

3-(1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-1H-1,2,3triazol-4-yl)phenol (42)

AcO
AcO

OAc
O

N N
N

OH

NHAc

2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -Dglucopyranosyl azide (100 mg, 0.27 mmol) and

the phenol 39 (21.2 µl, 0.32 mmol) were added to CuSO4.5H2O (13.5 mg, 0.05 mmol)
and sodium ascorbate (21.4 mg, 0.11 mmol) in a 1:1 mixture of tert-butanol/water (4
ml). The reaction mixture was stirred for 2.5 h at RT and then extracted with ethyl
acetate (2 x 20 ml). The organic extracts were combined, dried over anhydrous Na2SO4,
concentrated under reduced pressure and then purified using HPLC (RP Altima C18
column, flow rate = 50-300 mL/min, isocratic run 40% ACN, 50% H2O, 10%
NH4HCO3, tR = 7.7 min) to afford 42 (90 mg, 68%) as a white solid, m.p. 243-245 oC,
Rf 0.5 (silica, 80:20, CHCl3: MeOH).

∗

Denotes the minor isomer (ratio of isomers is 3:1 based on 1H NMR integrals).
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1

H-NMR (DMSO-d6)

1.59 (s, 3H, NHAc), 1.96 (s, 3H, OAc), 2.00 (s, 3H, OAc),

2.02 (s, 3H, OAc), 4.09 (bd, 1H, J = 12.0 Hz, H-6a), 4.17 (dd, 1H, J = 12.4 Hz, 4.7 Hz,
H-6b), 4.24 – 4.27 (m, 1H, H-5), 4.65 (q, 1H, J = 9.8 Hz, H-2), 5.11 (t, 1H, J = 9.9 Hz,
H-4), 5.38 (t, 1H, J = 10.1 Hz, H-3), 6.13 (d, 1H, J = 9.8 Hz, H-1), 6.76 (d, 1H, J = 7.2
Hz, NHAc), 7.25 (m, 3H, ArH), 8.11 (d, 1H, J = 9.0 Hz, ArH), 8.74 (s, 1H, H-triazole),
9.60 (s, 1H, OH).

13

C-NMR (DMSO-d6)

20.4 (OAc), 20.5 (OAc), 20.6 (OAc), 22.4

(NHAc), 52.4 (C-2), 61.7 (C-6), 68.2 (C-4), 72.5 (C-3), 73.5 (C-5), 85.0 (C-1), 112.1
(ArCH), 115.4 (ArC), 116.2 (ArCH), 120.3 (CH-triazole), 130.2 (ArCH), 131.5
(ArCH), 146.7 (C-triazole), 157.9 (ArCOH), 162.6 (C=O), 169.6 (C=O), 169.7 (C=O)
170.3 (C=O). MS: LRMS m/z (ES+) 513.3 (M + Na)+. HRMS calculated for
C22H26N4O9Na: 513.1597 found 513.1586.

5.3 Radiochemical synthesis
[18F]-4-Fluorobutyne (14)
18
F Aqueous H[ F]fluoride approximately 30 mCi, was added to a

18

2.5 ml round bottom vial containing a solution of Kryptofix (K222)
(130 µl in ACN) and K2CO3 (30 µL in H2O). The solvent was evaporated under a
stream of nitrogen at 100 °C with a reducing vacuum. This azeotropic drying was
repeated twice by further addition of anhydrous acetonitrile (2 x 1 ml). The precursor,
butynyl tosylate 21 (10 mg) was dissolved in CH3CN (2 ml) and added to the dried
K222.K2CO3.K18F complex. The reaction mixture was heated at 100 oC for 8 min,
during which the 4-[18F]fluoro-1-butyne (bp 45 oC) was distilled with acetonitrile into
another vial via an inert peak transfer line for use in the click reaction. After the
distillation, measurement of radioactivity indicated 12.3 mCi into the second vial
corresponding to a radiochemical yield of 50%.
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[18F]-1-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy- -D-glucopyranosyl)-4-(2fluoroethyl)-1H-1,2,3-triazole (12)
The 4-[18F]fluoro-1-butyne 14 was distilled with

OAc
AcO
AcO

O
NHAc

N N
N

18F

acetonitrile into a 2.5 ml round bottom vial
containing a solution of the 2-azido sugar (2)

(2.00 mg, 5.36 mmol), CuSO4.5H2O (3.1 mg, 16 µmol), sodium ascorbate (21 mg, 106
µmol) and CH3CN (500 µl) at -45 oC. After completing the distillation, DIPEA (21 µl,
120 µmol) and H2O (500 µl) was added to the reaction mixture. The reaction mixture
was heated at 90 oC for 8 min and the acetonitrile was evaporated for 5 min. The
reaction mixture was filtered using a Waters 0.45 µm GHP Acrodisc filter then
analysed by HPLC (Bondclone column 300 x 7.8 mm, flow rate = 4 ml/min, isocratic
run 20% ACN, 80% H2O and 0.1% TFA, tR = 7.0-13.4 min) to afford 12 with 741 µCi
corresponding to 22% radiochemical yield and 80% radiochemical purity. Co-injection
of the reaction mixture with the cold standard 8 confirmed the identity of the product
(12).
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Chapter 7: Appendices

Appendix 1: 1H-NMR spectra (400 MHz, CDCl3) of 1-(2-Acetamido-3,4,6-tri-Oacetyl-2-deoxy- -D-glucopyranosyl)-4-(hydroxyethyl)-1,2,3-triazole (6).
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NHAc

N N
N
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Appendix 2: 1H-NMR spectra (400 MHz, CDCl3) of 1-(2-Acetamido-3,4,6-O-acetyl-2deoxy-

- D-glucopyranosyl)-

)-(4-fluoromethyl) 1H- 1H-1,2,3-triazole (7)
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N N
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Appendix 3: 1H-NMR spectra (400 MHz, CDCl3) of 1-(2-Acetamido-3,4,6-O-acetyl-2deoxy-

- D-glucopyranosyl)-

)-(4-fluoroethyl) 1H- 1H-1,2,3-triazole (8)
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Appendix 4: 1H-NMR spectra (400 MHz, CDCl3) of (1-(Methyl 2,3,4-tri-O-acetyl- D-glucuronide)-1H-1,2,3-triazole-4-yl)methanol
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Appendix 5: 1H-NMR spectra (400 MHz, CDCl3) of (1-(Methyl 2,3,4-tri-O-acetyl- D-glucuronide)-1H-1,2,3-triazole-4-yl)ethanol

H3CO
AcO
AcO

(27)
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Appendix 6: 1H-NMR spectra (400 MHz, CDCl3) of ((1-(1-O-Tert-butyldimethylsilyl2-deoxy- -D-glucopyranosyl-3,4,6-tri-O-acetyl)-1H-1,2,3-triazol-4-yl)ethanol (34)
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Appendix 7: 1H-NMR spectra (400 MHz, DMSO-d6) of 3-(1-(Methyl 2,3,4-tri-O-acetyl- D-glucuronide)-1H-1,2,3-triazol-4-yl)phenol

H3 CO
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(41)
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Appendix 8: 1H-NMR spectra (400 MHz, DMSO-d6) of 3-(1-(2-Acetamido-3,4,6-Oacetyl-2-deoxy- - D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)phenol (42)
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